[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5817
1. Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN: Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer; 2010 Dec;9(4):507-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
  • Few studies have reported on the comprehensive BRCA1/2 mutation analyses of hereditary breast cancer (HBC) families of French Canadian descent.
  • Here we report the investigation of 82 families with at least 3 cases of breast cancer evaluated for mutations by DNA sequencing and/or multiplex ligation-dependent probe amplification (MLPA) assay.
  • A phenotypic characterization of the cancer families based on pathogenic mutation status revealed that there were significantly fewer very young age at diagnosis breast cancer cases (<36 years) in mutation-negative families (5.9%, 9 of 153) than in BRCA1 (22.8%, 13 of 57; P = 0.0003) or BRCA2 (22.9%, 27 of 118; P < 1× 10E5) mutation-positive families.
  • There were significantly more mutation-positive families (29 of 36, 80.6%) with a very young age of onset of breast cancer case than those that did not (8 of 39, 20.5%) (P < 10E6).
  • The comprehensive mutation analysis of BRCA1/2 suggests that genomic rearrangements are unlikely to account for sequence-negative HBC families and affirms that the presence of a very young age of diagnosis of breast cancer is strongly predictive of mutation carrier status of French Canadian HBC families.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Germ-Line Mutation / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Canada / epidemiology. Cohort Studies. DNA Mutational Analysis. DNA, Neoplasm / genetics. European Continental Ancestry Group / genetics. Female. Founder Effect. Genetic Predisposition to Disease. Genotype. Humans. Middle Aged. Polymerase Chain Reaction. Risk Factors


2. Wu M, Zhang H, Li X, Zhang Y, Su Z, Zhang C: Soil fungistasis and its relations to soil microbial composition and diversity: a case study of a series of soils with different fungistasis. J Environ Sci (China); 2008;20(7):871-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soil fungistasis and its relations to soil microbial composition and diversity: a case study of a series of soils with different fungistasis.
  • In this study, the bacterial community composition and diversity of a series of soils treated by autoclaving, which coming from the same original soil sample and showing gradient fungistasis to the target soil-borne pathogen fungi Fusarium graminearum, was investigated by soil bacterial 16S rDNA-PCR (polymerase chain reaction) cloning, restriction fragment length polymorphism (RFLP), and sequencing.

  • MedlinePlus Health Information. consumer health - Molds.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814585.001).
  • [ISSN] 1001-0742
  • [Journal-full-title] Journal of environmental sciences (China)
  • [ISO-abbreviation] J Environ Sci (China)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


3. Tausche AK, Sebastian G: Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix. Int Wound J; 2005 Sep;2(3):253-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix.
  • A case study reporting on the successful treatment of a patient affected by a basal cell carcinoma is submitted.
  • Because the carcinoma had infiltrated deeply, a wide excision was necessary, including the removal of bone tissue.
  • The deep tissue defect was treated with PROMOGRAN* Matrix, a protease-modulating matrix, to promote granulation and ensure that the skin graft do survive and heal successfully.
  • In this case study, a rapid development of granulation tissue on the exposed surface of the bone was observed.
  • The benefits of the dressing enabled a successful split-thickness skin grafting to be carried out which gave very good aesthetic and functional results.
  • [MeSH-major] Bandages, Hydrocolloid. Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery. Skin Transplantation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618330.001).
  • [ISSN] 1742-4801
  • [Journal-full-title] International wound journal
  • [ISO-abbreviation] Int Wound J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 9007-34-5 / Collagen
  •  go-up   go-down


Advertisement
4. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • The adjacent unaffected skin showed a normal number of melanocytes and melanin pigment.
  • To our knowledge, this is the first biopsy-proven case of vitiligo in an imiquimod-treated area.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Melanocytes / pathology. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


5. Aksoy B, Aksoy HM, Ustün H, Civaş E, Oç B, Atakan N: Basal cell carcinoma in a skin tag. Eur J Dermatol; 2008 Sep-Oct;18(5):605-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in a skin tag.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779117.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


6. Meyer N, Pruvost-Balland C, Bourdon-Lanoy E, Maubec E, Avri MF: Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. J Eur Acad Dermatol Venereol; 2007 Apr;21(4):520-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France.
  • BACKGROUND: The incidence of skin cancer has risen over the past years, owing to increased exposure to ultraviolet radiation.
  • We evaluated the knowledge and compliance with advices about sun protection in a population of patients who had presented skin tumour(s).
  • SUBJECTS AND METHODS: A 30 question self-reporting questionnaire evaluating sun protective behaviour was distributed to 217 consecutive skin cancer-treated patients and completed by 198 of them.
  • RESULTS: 72% of the responders had presented a melanoma, and 26% of them had presented only non-melanoma skin cancer.
  • The present survey shows that patients who have had a skin cancer were aware of the cancer related risk of sunlight since 98% of the responders knew that ultraviolet radiations can include skin cancer.
  • CONCLUSION: These results suggest that, after diagnosis of a skin cancer, patients limited their sun exposure; and wear protective clothing.
  • [MeSH-major] Attitude to Health. Health Knowledge, Attitudes, Practice. Radiation Protection. Skin Neoplasms / psychology. Sunlight / adverse effects. Sunscreening Agents / therapeutic use
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / psychology. Carcinoma, Basal Cell / therapy. Environmental Exposure. France. Health Behavior. Humans. Melanoma / psychology. Melanoma / therapy. Middle Aged. Patient Compliance. Protective Clothing. Recreation. Risk Factors. Skin Pigmentation. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Eur Acad Dermatol Venereol. 2008 May;22(5):646-7; author reply 647-8 [18384548.001]
  • (PMID = 17373981.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


7. Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, Calzavara-Pinton P, Varma S, Roelandts R, Wolf P: Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol; 2008 Sep-Oct;18(5):547-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial.
  • This multicentre, randomized study compared photodynamic therapy using topical methyl aminolaevulinate (MAL PDT), a non-invasive modality, with cryotherapy for treatment of superficial basal cell carcinoma.
  • These results provide support for the use of MAL PDT as a non-invasive, selective treatment alternative for primary superficial basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / therapy. Cryotherapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693158.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


8. Rashid K, Ng R, Mastan A, Sager D, Hirschman R: Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia. Leuk Lymphoma; 2005 Jul;46(7):1051-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
  • We present four patients with chronic lymphocytic leukemia treated with fludarabine, who developed aggressive skin cancer after years of quiescence, a short time after institution of treatment.
  • Three patients had recurrence with basal cell carcinomas with multiple, rapidly growing tumors and one had recurrence of both basal and squamous cancers and eventually died of metastatic squamous cell carcinoma.
  • Fludarabine induces prolonged period of lymphopenia, affecting especially the T cell population, which is crucial in the defense against skin cancers.
  • There appears to be a direct association between fludarabine and the flare up of skin cancers in these patients, possibly analogous to the increased incidence of these malignancies in patients on chronic cyclosporine immunosuppression.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / chemically induced. Carcinoma, Squamous Cell / chemically induced. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Skin Neoplasms / chemically induced. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019557.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


9. Schulman JM, Fisher DE: Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol; 2009 Mar;21(2):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indoor ultraviolet tanning and skin cancer: health risks and opportunities.
  • PURPOSE OF REVIEW: Skin cancer incidence is higher than that of any other human malignancy, and yet one of its root causes [ultraviolet (UV) radiation] is perhaps better understood than any other human carcinogen.
  • The roles of UV radiation exposure and indoor tanning behaviors on skin cancer risk are explored here.
  • RECENT FINDINGS: Studies from the past several years have shown a significant association between ever-use of an indoor tanning facility and an increased risk of basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • The association between indoor tanning and skin cancer is particularly strong among those who first used a tanning facility in early adulthood.
  • Elevated vitamin D levels have been suggested to protect against various internal malignancies and other disease states, but sources of vitamin D that do not require UV exposure are easily available.
  • SUMMARY: Although additional research is needed to understand fully the relationship between UV and skin cancer, it is already clear that indoor tanning bed use represents an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):88-102 [11684456.001]
  • [Cites] Health Policy. 2009 Mar;89(3):303-11 [18760857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):328-30 [7581459.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):589-96 [16546579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13765-70 [16954188.001]
  • [Cites] Nature. 2006 Sep 21;443(7109):340-4 [16988713.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):962-7 [17097392.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1116-22 [17131335.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):375-9 [17257709.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Arch Dermatol. 2007 Apr;143(4):529-32 [17438188.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):774-80 [17276543.001]
  • [Cites] Arch Intern Med. 2007 Jun 11;167(11):1159-65 [17563024.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 18;99(14):1120-9 [17623801.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):350-6 [17650177.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] PLoS Med. 2007 Mar;4(3):e103 [17388667.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] Int J Dermatol. 2007 Dec;46(12):1253-7 [18173518.001]
  • [Cites] Am J Health Behav. 2008 Sep-Oct;32(5):451-64 [18241130.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):272-83 [18353168.001]
  • [Cites] Dermatol Surg. 2008 Apr;34(4):460-74 [18248469.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):769-80 [18328594.001]
  • [Cites] Arch Dermatol. 2008 Apr;144(4):484-8 [18427042.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):796-804 [18505967.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):659-69 [18273687.001]
  • [Cites] Photochem Photobiol. 2008 Sep-Oct;84(5):1100-8 [18399922.001]
  • [Cites] Photochem Photobiol. 2008 Nov-Dec;84(6):1487-92 [18513233.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):224-6 [11830612.001]
  • (PMID = 19532016.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / AR058469-01; United States / NIAMS NIH HHS / AR / R01 AR043369; United States / NIAMS NIH HHS / AR / RC1 AR058469; United States / NIAMS NIH HHS / AR / RC1 AR058469-01
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 37
  • [Other-IDs] NLM/ NIHMS202769; NLM/ PMC2913608
  •  go-up   go-down


10. Patel R, Adsay V, Andea A: Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma. Rare Tumors; 2010;2(1):e8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma.
  • Merkel cell carcinoma (MCC) or primary cutaneous neuroendocrine carcinoma is a malignant tumor considered to demonstrate differentiation towards Merkel cells that are present at the base of the epidermis or around the apical end of some hair follicles and are thought to play a yet uncertain role in sensory transduction.
  • Here we present the case of a 54- year old female with a basal cell carcinoma (BCC) of the skin with neuroendocrine features (positivity for chromogranin) that has evolved during multiple recurrences and radiotherapy into a high-grade neuroendocrine carcinoma with morphological and immunohistochemical features of MCC (trabecular and nesting arrangement, positivity for chromogranin, cytokeratin 20, neuron specific enolase, and also neurosecretory granules on electron microscopy).
  • The progression from a chromogranin positive basal cell carcinoma of the skin, to a high-grade neuroendocrine carcinoma demonstrates the potential for cross differentiation among skin tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139953.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994488
  • [Keywords] NOTNLM ; Merkel cell carcinoma / basal cell carcinoma / neuroendocrine
  •  go-up   go-down


11. Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP: Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer; 2010 Feb 26;9:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The human cell cycle transcription factor FOXM1 is known to play a key role in regulating timely mitotic progression and accurate chromosomal segregation during cell division.
  • We previously showed that FOXM1 was upregulated in basal cell carcinoma and recently reported that upregulation of FOXM1 precedes malignancy in a number of solid human cancer types including oral, oesophagus, lung, breast, kidney, bladder and uterus.
  • This indicates that upregulation of FOXM1 may be an early molecular signal required for aberrant cell cycle and cancer initiation.
  • RESULTS: The present study investigated the putative early mechanism of UVB and FOXM1 in skin cancer initiation.
  • We have demonstrated that UVB dose-dependently increased FOXM1 protein levels through protein stabilisation and accumulation rather than de novo mRNA expression in human epidermal keratinocytes.
  • FOXM1 upregulation in primary human keratinocytes triggered pro-apoptotic/DNA-damage checkpoint response genes such as p21, p38 MAPK, p53 and PARP, however, without causing significant cell cycle arrest or cell death.
  • FOXM1-induced genomic instability was significantly enhanced and accumulated with increasing cell passage and this instability was increased even further upon exposure to UVB resulting in whole chromosomal gain (7p21.3-7q36.3) and segmental LOH (6q25.1-6q25.3).
  • CONCLUSION: We hypothesise that prolonged and repeated UVB exposure selects for skin cells bearing stable FOXM1 protein causes aberrant cell cycle checkpoint thereby allowing ectopic cell cycle entry and subsequent genomic instability.
  • The aberrant upregulation of FOXM1 serves as a 'first hit' where cells acquire genomic instability which in turn predisposes cells to a 'second hit' whereby DNA-damage checkpoint response (eg. p53 or p16) is abolished to allow damaged cells to proliferate and accumulate genetic aberrations/mutations required for cancer initiation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2009 Apr 10;302(1):41-8 [19101605.001]
  • [Cites] PLoS One. 2009;4(3):e4849 [19287496.001]
  • [Cites] Mol Cancer Res. 2010 Jan;8(1):24-34 [20068070.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]
  • [Cites] Head Neck. 2001 Feb;23(2):104-12 [11303627.001]
  • [Cites] Nature. 2001 May 3;411(6833):102-7 [11333986.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1404-14 [11391529.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Science. 2002 Apr 19;296(5567):530-4 [11964479.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4773-80 [12183437.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44310-6 [12221098.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16881-6 [12482952.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):991-7 [12631597.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2993-3006 [12771951.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):611-22 [19246619.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1966-7 [19411834.001]
  • [Cites] Oncogene. 2009 Dec 3;28(48):4295-305 [19749794.001]
  • [Cites] Cell. 2003 Sep 5;114(5):599-610 [13678583.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6266-76 [13679865.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1479-85 [14562020.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2160-3 [14562369.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2397-403 [14668223.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2708-14 [14669293.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1317-30 [15175263.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45721-7 [15322085.001]
  • [Cites] Oncogene Res. 1987 Jul;1(2):169-78 [3329713.001]
  • [Cites] Cell. 1994 Sep 9;78(5):761-71 [8087844.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1626-41 [9032290.001]
  • [Cites] Nucleic Acids Res. 1997 May 1;25(9):1715-9 [9108152.001]
  • [Cites] Curr Biol. 1998 Dec 3;8(24):1327-30 [9843684.001]
  • [Cites] Genomics. 1999 Oct 1;61(1):66-73 [10512681.001]
  • [Cites] Trends Mol Med. 2004 Nov;10(11):542-8 [15519280.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Oncol Res. 2005;15(1):49-57 [15839305.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Ann Surg Oncol. 2005 Oct;12(10):831-42 [16132373.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8597-603 [16204023.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):719-29 [16222316.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2829-38 [16407842.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):92-102 [17014965.001]
  • [Cites] J Cell Sci. 2007 Jan 15;120(Pt 2):330-9 [17200136.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(3):1007-16 [17101782.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1434-43 [17205517.001]
  • [Cites] Bioinformatics. 2007 Feb 15;23(4):496-7 [17138589.001]
  • [Cites] Nat Cell Biol. 2007 May;9(5):493-505 [17450133.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1167-72 [17577780.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):18922-8 [17470428.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):111-8 [17442483.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):911-24 [18004399.001]
  • [Cites] Cancer Lett. 2008 Feb 8;259(2):177-85 [18037232.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1037-42 [18205184.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1834-42 [18339864.001]
  • [Cites] Cancer Biol Ther. 2008 Jun;7(6):958-65 [18379196.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26876-83 [16803887.001]
  • [Cites] J Cell Sci. 2008 Oct 1;121(Pt 19):3271-82 [18782865.001]
  • (PMID = 20187950.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ PMC2907729
  •  go-up   go-down


12. Arbiser JL: Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma. Cancer Prev Res (Phila); 2010 Jan;3(1):4-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.
  • This different perspective on Tang et al. (beginning on p. 25 in this issue of the journal) discusses the pivotal role of cyclooxygenase (COX) signaling in the pathogenesis of basal cell carcinoma (BCC).
  • These investigators conducted elegant experiments showing increased BCC burden in patch heterozygous mice overexpressing COX-2 in the epidermis.
  • Genetic deletion of COX-1 or COX-2 resulted in a robust decrease in BCC burden in patch heterozygote mice.
  • They then studied pharmacologic COX inhibition in mice and humans with loss of patch, finding a trend in humans toward decreased BCC burden.
  • This finding has implications for public health.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2007 Aug;21(10):2418-30 [17384145.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):621-33 [16966432.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):1019-28 [18178842.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4267-74 [18594009.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5743-8 [18794083.001]
  • [Cites] Int J Hematol. 2009 Apr;89(3):332-41 [19263190.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1055-61 [19701205.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7224-34 [19738049.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] J Biol Chem. 2009 Nov 20;284(47):32264-71 [19808686.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7654-64 [17699770.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Mol Med. 1998 Jun;4(6):376-83 [10780880.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2239-46 [10786690.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):885-8 [9620294.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5870-4 [15576369.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32 [16203784.001]
  • [CommentOn] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • (PMID = 20051366.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] None / None / / R01 AR047901-06A2; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / R01 AR02030; United States / NIAMS NIH HHS / AR / AR050727-01A1; United States / NIAMS NIH HHS / AR / R01 AR047901-06A2; United States / NIAMS NIH HHS / AR / R01 AR050727-01A1; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS162367; NLM/ PMC3154731
  •  go-up   go-down


13. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A, Wolf P: Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol; 2007 Sep;143(9):1131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
  • OBJECTIVE: To compare 5-year lesion recurrence rates in primary nodular basal cell carcinoma treated with topical methyl aminolevulinate photodynamic therapy (PDT) or simple excision surgery.
  • CONCLUSIONS: Long-term follow-up indicates superior efficacy of surgery to methyl aminolevulinate PDT in nodular basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Ointments


14. Steele CL, Shea CR, Petronic-Rosic V: Epidermolytic hyperkeratosis within infundibular cysts. J Cutan Pathol; 2007 Apr;34(4):360-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EH has been observed as an incidental finding in tissue adjacent to and within lesions such as nevi, scars, malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and seborrheic keratoses.
  • We present two cases of EH within infundibular type follicular cysts, a rare finding only once otherwise reported in 1978.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / complications. Carcinoma, Squamous Cell / complications. Female. Humans. Incidental Findings. Male. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381810.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


15. Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL: Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol; 2005 Sep;29(9):1152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases.
  • Sarcomatoid carcinomas are uncommon, high-grade tumors, predominantly composed of spindle cells.
  • Only a few cases arising in the penis have been reported.
  • The aim of this study is to better define the clinicopathologic features of this neoplasm.
  • A total of 400 cases of squamous cell carcinoma of the penis were reviewed from which 15 sarcomatoid carcinomas (4%) were identified.
  • Clinical and pathologic features were evaluated in all cases.
  • Immunohistochemical studies for expression of AE1/AE3, Cam 5.2, 34betaE12, EMA, vimentin, muscle specific actin, smooth muscle actin, desmin, S-100, p63, and p53 and in situ hybridization studies for HPV were performed in 5 cases.
  • Information about lymph node status was available in 9 cases, and follow-up in 5 cases.
  • Grossly, most tumors were large, polypoid, and ulcerated masses frequently affecting the glans (93%) and deeply invading corpora cavernosa (80%) and skin.
  • Microscopically, the lesions were predominantly composed of atypical spindle cells disposed in interlacing fascicles, resembling fibrosarcoma or leiomyosarcoma, sometimes admixed with pleomorphic giant cells mimicking malignant fibrous histiocytoma.
  • One case was predominantly composed of myxoid areas.
  • Foci of heterologous differentiation toward bone (osteosarcomatous component) were present in 1 case.
  • Four cases showed a minor mixed component of usual, papillary, verrucous, and basaloid carcinoma.
  • One of the cases was multicentric with a separate independent focus of well-differentiated carcinoma with pseudohyperplastic features.
  • Associated low- and high-grade squamous intraepithelial lesions were noted in 73% of the cases.
  • Immunohistochemical studies and HPV in situ hybridization were done in 5 cases.
  • The spindle cells were diffusely positive for vimentin and p53 and showed at least intermediate expression of 34betaE12 and p63 in all cases.
  • EMA and AE1/AE3 were focally positive in 60% of the cases, and Cam 5.2 was focally positive in 1 case.
  • HPV in situ hybridization was negative in all cases.
  • Inguinal metastases were present in 89% of the cases.
  • Two of five patients with adequate follow-up died of disease within 8 months of the diagnoses.
  • In conclusion, penile sarcomatoid carcinomas are unusual, large, and aggressive tumors usually associated with lymph node metastasis and poor outcome.
  • Diffuse immunoreactivity for p53, compared with a more basal and focal reactivity in differentiated squamous cell carcinoma, may be indicative of a late mutation in the natural progression of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096403.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Giersig C: Progestin and breast cancer. The missing pieces of a puzzle. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul;51(7):782-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progestin and breast cancer. The missing pieces of a puzzle.
  • The previous assumption that progestin does not promote breast cancer development needs to be re-examined since a growing body of evidence indicates the opposite.
  • Data from recent experimental trials and results from clinical and epidemiological studies on hormonal contraceptives and hormone replacement therapy (HRT) have been confronted with breast cancer cases known from the German database of adverse drug reactions (ADR), reported in association with the use of progestin only contraceptives (POC) and combined oral contraceptives (COC).
  • Also cases reported in association with HRT have been analysed.
  • The available data complement one another showing a tumour promoting potential of progestin, possibly higher than that of a combination of estrogen and progestin.
  • 1) in estrogen-supplemented animals, progesterone has been shown to reactivate the growth of regressed tumour xenograft obtained from breast cancer cell lines, expressing both estrogen and progesterone receptor;.
  • 2) antiprogestin has been revealed to suppress the reactivation of the growth of tumour xenograft and to fully suppress the development of breast cancer in an animal model for BRCA1 gene mutation;.
  • 3) metabolites of progesterone have been recognised as potent regulators of cell proliferation, cell detachment and apoptosis;.
  • 4) progesterone has been shown to inhibit, in a dose-dependent manner, apoptosis in breast cancer cell lines and apoptosis induced by doxorubicin and 5-fluorouracyl (drugs used in breast cancer treatment);.
  • 5) an association between breast cancer and HRT was suspected upon the addition of progestin on a regular basis for the prevention of endometrial cancer;.
  • 6) in a randomised placebo-controlled trial on HRT an increased risk of breast cancer was shown for the combination of estrogen and progestin, but not for estrogen alone;.
  • 7) in epidemiological studies on POC the recognition of an increased breast cancer risk was most probably impeded due to previously unrecognised systematic selection bias;.
  • 8) in a large epidemiological study on the risk of early-onset breast cancer in association with COC an increased risk was detected for COC use up to 1975, but no increased, even a slightly decreased, risk was shown for users of low-dose COC, applied since 1976;.
  • 9) a considerably higher number of breast cancer cases have been reported from Germany on POC than on the widespread used COC [corrected] (111 versus 12);.
  • 10) the big resemblance among the breast cancers reported for POC and their similarity with breast malignancies diagnosed in pregnancy suggest the existence of a pattern rather than pure coincidence [corrected]
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / prevention & control. Contraception / statistics & numerical data. Contraceptives, Oral, Hormonal. Progestins. Risk Assessment / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Birth Control.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):779-81 [18592337.001]
  • [ErratumIn] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Aug;51(8):946
  • (PMID = 18592338.001).
  • [ISSN] 1436-9990
  • [Journal-full-title] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
  • [ISO-abbreviation] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 0 / Progestins
  • [Number-of-references] 21
  •  go-up   go-down


17. Betz CS, Rauschning W, Stranadko EP, Riabov MV, Albrecht V, Nifantiev NE, Hopper C: Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas. Lasers Surg Med; 2008 Jul;40(5):300-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas.
  • BACKGROUND AND OBJECTIVE: Basal cell carcinomas (BCCs) are the most common form of skin cancers with high and increasing incidence rates.
  • STUDY DESIGN/MATERIALS AND METHODS: mTHPC-PDT was performed in 117 patients with a total of 460 BCCs with diagnosis confirmed by scratch cytology.
  • CONCLUSIONS: The presented data suggest that mTHPC-PDT with the treatment parameters mentioned above seems to be an effective treatment option for BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563776.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


18. Seyhan T, Caglar B: "Reading man flap" design for reconstruction of circular infraorbital and malar skin defects. Dermatol Surg; 2008 Nov;34(11):1536-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Reading man flap" design for reconstruction of circular infraorbital and malar skin defects.
  • BACKGROUND: Surgical complications such as lid retraction and ectropion from graft or flap scar contracture make reconstruction of skin defects in the malar and infraorbital regions challenging.
  • METHODS: The reading man flap consists mainly of a superiorly based quadrangular flap and an inferiorly based triangular flap.
  • Malar and infraorbital circular skin defects measuring 14 x 14 to 40 x 40 mm were reconstructed with a reading man flap in 13 patients.
  • The defects occurred after basal cell carcinoma in all patients.
  • The results were compared in terms of total scar area, scar length, and total healthy skin area discarded.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Face / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798751.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Dögnitz N, Salomon D, Zellweger M, Ballini JP, Gabrecht T, Lange N, van den Bergh H, Wagnières G: Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. J Photochem Photobiol B; 2008 Dec 11;93(3):140-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma.
  • Photodynamic therapy (PDT) based on the use of photoactivable porphyrins, such as protoporphyrin IX (PpIX), induced by the topical application of amino-levulinic acid (ALA) or its derivatives, ALA methyl-ester (m-ALA), is a treatment for superficial basal cell carcinoma (BCC), with complete response rates of over 80%.
  • However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX.
  • Previous in vitro skin permeation studies demonstrated an increased penetration of amino-levulinic acid hexyl-ester (h-ALA) over ALA.
  • In this study, we tested the validity of this approach in vivo on human BCCs.
  • An emulsion containing 20% ALA (w/w) and preparations of h-ALA at different concentrations were applied topically to the normal skin of Caucasian volunteers to compare the PpIX fluorescence intensities with an optical fiber-based spectrofluorometer.
  • In addition, the PpIX depth distribution and fluorescence intensity in 26 BCCs were investigated by fluorescence microscopy following topical application of 20% ALA and 1% h-ALA.
  • We found that, for application times up to 24h, h-ALA is identical to ALA as a PpIX precursor with respect to PpIX fluorescence intensity, depth of penetration, and distribution in basal cell carcinoma, but has the added advantage that much smaller h-ALA concentrations can be used (up to a factor 13).
  • We observed a non-homogenous distribution in BCCs with both precursors, independent of the histological type and depth of invasion in the dermis.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / metabolism. Photosensitizing Agents / administration & dosage. Protoporphyrins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818091.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


20. Molina Garrido MJ, Guillén Ponce C, Soto Martínez JL, Martínez Y Sevila C, Carrato Mena A: Cutaneous metastases of lung cancer. Clin Transl Oncol; 2006 May;8(5):330-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases of lung cancer.
  • It is uncommon for a cancer to be diagnosed because of skin metastases.
  • Cutaneous metastases as initial manifestation of internal neoplasias, represent only 0.8% of total cases and implies, in general, a very advanced grade of the disease and short survival.
  • When skin metastases of an unknown primary site appear, lung cancer is the first option to be discarded in case of men, and breast cancer in case of women.
  • Lung cancer spreads to the skin in 2.8-8.7% of the cases, in advanced phases of the disease, although just in 7-23.8% of the cases, cutaneous metastases appear as first manifestation of the primary tumor.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / pathology. Prospective Studies. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1994 Nov;106(5):1448-50 [7956399.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Jan;29(1):95-100 [1645818.001]
  • [Cites] CA Cancer J Clin. 1986 May-Jun;36(3):130-48 [3011224.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):57-61 [11115569.001]
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):19-26 [2298962.001]
  • [Cites] Postgrad Med J. 1995 Dec;71(842):741-3 [8552539.001]
  • [Cites] Med Clin North Am. 1980 Sep;64(5):885-900 [7432046.001]
  • [Cites] Chest. 1990 Mar;97(3):757-9 [2155089.001]
  • [Cites] Med Clin (Barc). 1992 Mar 28;98(12):477 [1573920.001]
  • [Cites] Postgrad Med. 1986 Dec;80(8):111-6 [3786272.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Jun;95(6):994-7 [2836663.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2002 Aug;50(8):343-6 [12229219.001]
  • [Cites] Intern Med. 1996 Jun;35(6):459-62 [8835596.001]
  • [Cites] Arch Dermatol. 1981 Feb;117(2):120-1 [7469434.001]
  • [Cites] Gan No Rinsho. 1988 Jul;34(8):1054-6 [3404658.001]
  • [Cites] Arch Bronconeumol. 1994 Jun-Jul;30(6):314-6 [8087393.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 May;57(5):343-7 [8768382.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • (PMID = 16760007.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 19
  •  go-up   go-down


21. Becker TL, Paquette AD, Keymel KR, Henderson BW, Sunar U: Monitoring blood flow responses during topical ALA-PDT. Biomed Opt Express; 2010 Dec 15;2(1):123-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) is currently used as a clinical treatment for nonmelanoma skin cancers.
  • We present blood flow responses to topical ALA-PDT in a preclinical model and basal cell carcinoma patients assessed by diffuse correlation spectroscopy (DCS).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 1984 Dec;29(12):1463-76 [6240065.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1113-9 [7577455.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Acta Derm Venereol. 2005;85(6):483-90 [16396794.001]
  • [Cites] Photochem Photobiol Sci. 2006 May;5(5):452-8 [16685321.001]
  • [Cites] Photochem Photobiol. 2006 Sep-Oct;82(5):1279-84 [16696593.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064021 [17212544.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051903 [17994886.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4475-83 [18628462.001]
  • [Cites] Ther Clin Risk Manag. 2008 Feb;4(1):1-9 [18728698.001]
  • [Cites] Opt Express. 2007 Nov 12;15(23):15507-16 [19550836.001]
  • [Cites] Photochem Photobiol Sci. 2009 Dec;8(12):1683-93 [20024165.001]
  • [Cites] J Biomed Opt. 2010 Mar-Apr;15(2):026028 [20459273.001]
  • [Cites] Opt Express. 2010 Jul 5;18(14):14969-78 [20639983.001]
  • [Cites] Appl Opt. 1995 Jun 20;34(18):3546-53 [21052170.001]
  • [Cites] Photochem Photobiol. 1995 Oct;62(4):780-9 [7480155.001]
  • [Cites] Photochem Photobiol. 1998 Jun;67(6):612-25 [9648527.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):184-9 [9068729.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3543-52 [15867258.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):818-24 [1616853.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Photochem Photobiol. 1999 Dec;70(6):921-9 [10628304.001]
  • [Cites] J Photochem Photobiol B. 1999 Sep-Oct;52(1-3):99-104 [10643075.001]
  • [Cites] J Am Acad Dermatol. 2000 Mar;42(3):389-413; quiz 414-6 [10688709.001]
  • [Cites] Acta Derm Venereol. 2000 Jan-Feb;80(1):19-23 [10721826.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):319-24 [11255332.001]
  • [Cites] Phys Med Biol. 2001 Aug;46(8):2053-65 [11512610.001]
  • [Cites] J Pathol. 2003 Jul;200(3):308-13 [12845626.001]
  • (PMID = 21326642.001).
  • [ISSN] 2156-7085
  • [Journal-full-title] Biomedical optics express
  • [ISO-abbreviation] Biomed Opt Express
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055791
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3028487
  • [Keywords] NOTNLM ; (170.0170) Medical optics and biotechnology / (170.3660) Light propagation in tissues / (170.3880) Medical and biological imaging / (170.6480) Spectroscopy, speckle
  •  go-up   go-down


22. Samolyuk GD, Miller GJ: Relation between chemical bonding and exchange coupling approaches to the description of ordering in itinerant magnets. J Comput Chem; 2008 Oct;29(13):2177-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the crossing theorem of Heine and Samson, the effective exchange coupling changes sign from negative (antiferromagnetic ordering) in the middle of 3d band to positive (ferromagnetic ordering) for the nearly empty or nearly filled d band cases.
  • The general character of these dependencies is demonstrated for various examples containing the magnetically active 3d metals, examples that include the bcc metals, Heusler alloys, and a series of novel quaternary intermetallic borides.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18566981.001).
  • [ISSN] 1096-987X
  • [Journal-full-title] Journal of computational chemistry
  • [ISO-abbreviation] J Comput Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Liboutet M, Portela M, Delestaing G, Vilmer C, Dupin N, Gorin I, Saiag P, Lebbé C, Kerob D, Dubertret L, Grandchamp B, Basset-Seguin N, Soufir N: MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol; 2006 Jul;126(7):1510-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas.
  • In this study, we assessed the role of melanocortin 1 receptor (MC1R) variants and of two patched (PTCH) polymorphisms (c.3944C>T (P1315L), insertion 18 bp IVS1-83) as risk factors for basal cell carcinoma (BCC) in the French population.
  • The population investigated comprised 126 BCC patients who were enrolled on the basis of specific criteria (multiple and/or familial BCC and/or onset before the age of 40 years and/or association with another tumor)--and 151 controls matched for ethnicity, age, and sex.
  • MC1R variants appeared as a moderate risk factor for BCC (odds ratio (OR) for one and two variants, 2.17 [1.28-3.68] and 7.72 [3.42-17.38], respectively), independently of pigmentation characteristics (OR = 2.53 [1.34-4.8]).
  • Interestingly, in addition to the predictable red hair color (RHC) alleles, two non-RHC alleles (V60L and V92M) were also closely associated with BCC risk (OR 3.21 [1.91-5.38] and 2.87 [1.5-5.48], respectively), which differs from the situation in the Celtic population.
  • In addition, the PTCH c.3944C/C genotype was also associated with BCC risk (OR 1.94 [1.2-3.1]), especially in the subgroup of patients with multiple tumors (OR 2.16 [1.3-3.6]).
  • Thus, our data show that MC1R and PTCH variants are associated with BCC risk in the French population.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Genetic. Receptor, Melanocortin, Type 1 / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. European Continental Ancestry Group / genetics. Female. France / ethnology. Gene Frequency. Genetic Predisposition to Disease. Hair Color. Humans. Male. Middle Aged. Odds Ratio. Prospective Studies. Regression Analysis. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645598.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


24. Mogensen M, Nürnberg BM, Forman JL, Thomsen JB, Thrane L, Jemec GB: In vivo thickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound. Br J Dermatol; 2009 May;160(5):1026-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo thickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound.
  • BACKGROUND: Accurate assessment of tumour size is important when planning treatment of nonmelanoma skin cancer (NMSC).
  • METHODS: In total, 93 patients were scanned and 34 lesions [23 basal cell carcinoma (BCC) and 11 actinic keratosis (AK) lesions] < 2 mm thick and easily identified in OCT images were studied.
  • The influence of skin pigmentation and infiltration analgesia on OCT image quality was studied.
  • Skin colour was measured with a colorimeter.
  • No relation between OCT penetration depth and skin colour was found.
  • CONCLUSIONS: OCT appears more precise and less biased than HFUS for thickness measurement in AK and BCC lesions < 2 mm, but both OCT and especially HFUS tended to overestimate tumour thickness.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Actinic / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2014 Mar;170(3):737-9 [24124649.001]
  • (PMID = 19183171.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Lonsdorf AS, Becker MR, Stockfleth E, Schäkel K, Ulrich C: [Primary and secondary prevention of skin cancer in organ transplant recipients]. Hautarzt; 2010 Mar;61(3):195-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary and secondary prevention of skin cancer in organ transplant recipients].
  • Skin cancer constitutes the most frequently reported post-transplant malignancy in solid organ transplant recipients (OTR) worldwide.
  • Whereas the risk for malignant melanoma is only moderately increased, non-melanoma skin cancers (NMSC) seem to thrive on chronic immunosuppression and account for up to 95% of post-transplant cutaneous malignancies.
  • Compared to the general population cutaneous squamous cell carcinoma (SCC) and actinic keratoses (AK) characteristically show even higher incidences than basal cell carcinoma (BCC) and act as an indicator for the development of multiple primary cutaneous neoplasias and locally recurrent cancers (field cancerization).
  • Early diagnosis and therapy of pre-malignant cutaneous lesions is crucial for the secondary prophylaxis of further invasive and highly aggressive skin cancers.
  • High quality interdisciplinary care and prophylactic modalities, including consistent and sufficient UV protection, topical immunmodulatory therapies of UV-damaged skin areas, retinoid chemoprevention as well as tapering immunosuppressive treatment or the selection of immunosuppressants with proposed antiangiogenic properties like mTor-inhibitors may help to reduce the multiplicity of subsequent primary skin cancers in high-risk patients.
  • Apart from the continuous need for educational intervention of OTR in the primary prophylaxis of post-transplant skin cancers, dermatologic care occupies a central position within the field of transplantation medicine in terms of pre- and post-transplantation dermatologic evaluation and therapy as well as the implication of timely and effective secondary preventive approaches in the management of this high-risk patient population.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / adverse effects. Primary Prevention / methods. Secondary Prevention / methods. Skin Neoplasms / etiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):28-33 [15842610.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] Lancet. 1992 Jul 4;340(8810):48-9 [1351617.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):978-82 [16103326.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):395-400 [16445766.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):628-33 [15061847.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):37-41 [10886505.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2):189-96 [14726871.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):985-93 [16103328.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):656-61 [15061851.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Br J Dermatol. 1999 Apr;140(4):656-60 [10233316.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):407-12 [12963902.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:78-84 [19775361.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] Methods. 2002 Sep;28(1):55-62 [12231188.001]
  • [Cites] Am J Transplant. 2005 Sep;5(9):2079-84 [16095486.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:109-15 [11795429.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):1015-6 [15313829.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Br J Dermatol. 2002 Oct;147(4):816-8 [12366444.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):837-45 [15491425.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):916-25 [17034519.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):53-61 [11326316.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):623-8 [9500317.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 20177652.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


26. Han J, Kraft P, Colditz GA, Wong J, Hunter DJ: Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer; 2006 Oct 15;119(8):1976-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocortin 1 receptor variants and skin cancer risk.
  • Melanocortin 1 receptor (MC1R) gene variants are associated with red hair and fair skin color.
  • We assessed the associations of common MC1R genotypes with the risks of 3 types of skin cancer simultaneously in a nested case-control study within the Nurses' Health Study (219 melanoma, 286 squamous cell carcinoma (SCC), and 300 basal cell carcinoma (BCC) cases, and 873 controls).
  • We found that the 151Cys, 160Trp and 294His variants were significantly associated with red hair, fair skin color and childhood tanning tendency.
  • The MC1R variants, especially the 151Cys variant, were associated with increased risks of the 3 types of skin cancer, after controlling for hair color, skin color and other skin cancer risk factors.
  • Carriers of the 151Cys variant had an OR of 1.65 (95% CI, 1.04-2.59) for melanoma, 1.67 (1.12-2.49) for SCC and 1.56 (1.03-2.34) for BCC.
  • Women with medium or olive skin color carrying 1 nonred hair color allele and 1 red hair color allele had the highest risk of melanoma.
  • The information on MC1R status modestly improved the risk prediction; the increase was significant for melanoma and BCC (p, 0.004 and 0.05, respectively).
  • These findings indicated that the effects of the MC1R variants on skin cancer risk were independent from self-reported phenotypic pigmentation.
  • [MeSH-major] Receptor, Melanocortin, Type 1 / genetics. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Color. Female. Genetic Variation / genetics. Genotype. Hair. Haplotypes / genetics. Humans. Middle Aged. Risk Factors. Sunlight

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16721784.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA113100; United States / NCI NIH HHS / CA / CA87969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Melanocortin, Type 1
  •  go-up   go-down


27. Scalvenzi M, Francia MG, Falleti J, Balato A: Basal cell carcinoma with fibroepithelioma-like histology in a healthy child: report and review of the literature. Pediatr Dermatol; 2008 May-Jun;25(3):359-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with fibroepithelioma-like histology in a healthy child: report and review of the literature.
  • We report the case of a 13-year-old girl with a 7 mm plaque on the trunk.
  • In 2003 a dermoscopic examination was executed and a diagnosis of dermical nevus was made.
  • A diagnosis of basal cell carcinoma was made and confirmed by histopathologic examination.
  • Basal cell carcinoma occurs rarely in children and is most often associated with an underlying condition that predisposes patients to the development of malignancy that was not present in our case.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dermoscopy. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577044.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


28. Lynch JP 3rd: Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med; 2009 Oct;30(5):596-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion.
  • Burkholderia cepacia complex (Bcc) is a group of phenotypically similar nonfermenting, aerobic, gram-negative rods that infect 2 to 8% of patients with cystic fibrosis (CF).
  • Bcc comprises several distinct species (formerly termed genomovars).
  • Infection with Bcc has been associated with worse outcomes and survival in CF patients.
  • Additionally, colonization with Bcc has been associated with heightened mortality following lung transplantation.
  • Currently, the role of lung transplantation in Bcc-infected patients remains controversial.
  • Antimicrobial therapy for Bcc is often ineffective because most strains are multidrug resistant.
  • Several genes or gene products have important roles in virulence, persistence of the organism(s), and transmissibility.
  • The incidence of Bcc and specific species fluctuates over time and between centers.
  • Bcc can be transmitted by social contact, and several major epidemic strains have disseminated globally.
  • [MeSH-major] Burkholderia Infections / physiopathology. Burkholderia cepacia complex / isolation & purification. Cystic Fibrosis / physiopathology

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Thieme Medical Publishers.
  • (PMID = 19760547.001).
  • [ISSN] 1098-9048
  • [Journal-full-title] Seminars in respiratory and critical care medicine
  • [ISO-abbreviation] Semin Respir Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 176
  •  go-up   go-down


29. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM: Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res; 2010 Apr 15;70(8):3287-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.
  • Small GTPase Ras homologue enriched in brain (RHEB) binds and activates the key metabolic regulator mTORC1, which has an important role in cancer cells, but the role of RHEB in cancer pathogenesis has not been shown.
  • By performing a meta-analysis of published cancer cytogenetic and transcriptome databases, we defined a gain of chromosome 7q36.1-q36.3 containing the RHEB locus, an overexpression of RHEB mRNA in several different carcinoma histotypes, and an association between RHEB upregulation and poor prognosis in breast and head and neck cancers.
  • To model gain of function in epithelial malignancy, we targeted Rheb expression to murine basal keratinocytes of transgenic mice at levels similar to those that occur in human squamous cancer cell lines.
  • Juvenile transgenic epidermis displayed constitutive mTORC1 pathway activation, elevated cyclin D1 protein, and diffuse skin hyperplasia.
  • Skin tumors subsequently developed with concomitant stromal angio-inflammatory foci, evidencing induction of an epidermal hypoxia-inducible factor-1 transcriptional program, and paracrine feed-forward activation of the interleukin-6-signal transducer and activator of transcription 3 pathway.
  • Rheb markedly sensitized transgenic epidermis to squamous carcinoma induction following a single dose of Ras-activating carcinogen 7,12-dimethylbenz(a)anthracene.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Curr Biol. 2000 Jan 13;10(1):47-50 [10660304.001]
  • [Cites] J Histochem Cytochem. 2009 Jul;57(7):649-63 [19289554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Genes Dev. 2001 Oct 1;15(19):2520-32 [11581158.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):129-40 [11896568.001]
  • [Cites] Cancer Cell. 2004 May;5(5):489-500 [15144956.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):720-8 [15343391.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Nat Med. 2005 Jan;11(1):43-9 [15592573.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):78-84 [16359855.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] J Urol. 2007 Jan;177(1):346-52 [17162089.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:443-67 [16968213.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):316-23 [17277771.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):209-16 [17276050.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):903-15 [17386266.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):667-81 [17600126.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Curr Biol. 2008 Jan 8;18(1):56-62 [18164202.001]
  • [Cites] Breast Cancer Res. 2007;9(4):212 [17705880.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1167-71 [18281551.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3343-54 [18199827.001]
  • [Cites] Mol Cell. 2008 Apr 25;30(2):214-26 [18439900.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):799-809 [18471051.001]
  • [Cites] Genes Dev. 2008 Aug 15;22(16):2172-7 [18708577.001]
  • [Cites] Genes Dev. 2008 Aug 15;22(16):2178-88 [18708578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13544-9 [18768809.001]
  • [Cites] Pathology. 2009 Jan;41(1):40-7 [19089739.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):91-102 [19185844.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):103-13 [19185845.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • (PMID = 20388784.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101012-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258; United States / PHS HHS / / R01-101012; United States / NCI NIH HHS / CA / R01 CA101012; United States / NCI NIH HHS / CA / CA101012-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Multiprotein Complexes; 0 / Neuropeptides; 0 / Proteins; 0 / RHEB protein, human; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS178666; NLM/ PMC2855737
  •  go-up   go-down


31. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P, Hereditary Breast Cancer Clinical Study Group: Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol; 2006 May;7(5):402-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
  • BACKGROUND: Screening mammography is associated with a small dose of radiation to the breast, and women with increased genetic risk might be particularly sensitive to the DNA-damaging effects of ionising radiation.
  • We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
  • METHODS: We identified 1600 cases of breast cancer and 1600 controls without breast cancer who were matched for BRCA mutation, date of birth (within 1 year), and country of residence from an international registry of BRCA1 and BRCA2 mutation carriers.
  • RESULTS: We found no association between ever having screening mammography and risk of breast cancer (odds ratio [OR] 1.03 [95% CI 0.85-1.25], adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy).
  • INTERPRETATION: These findings do not lend support to the idea that exposure to ionising radiation through routine screening mammography contributes substantially to the burden of breast cancer in BRCA1 and BRCA2 mutation carriers.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / epidemiology. Mammography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Mass Screening. Middle Aged. Mutation. Risk Factors


32. Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, Dunning AM: Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev; 2006 Apr;15(4):675-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach.
  • Association studies on susceptibility to breast cancer using single nucleotide polymorphisms (SNP) in the progesterone receptor (PGR) gene have been previously published, but the results have been inconclusive.
  • We used a comprehensive SNP-tagging approach to search for low-penetrance susceptibility alleles in a study of up to 4,647 cases and 4,564 controls, in a two-stage study design.
  • We identified seven tagging SNPs using genotype data from the National Institute of Environmental Health Sciences (NIEHS) Environmental Genome Project and typed these, and an additional three SNPs, in 2,345 breast cancer cases and 2,284 controls (set 1).
  • After both stages, only one SNP was significantly associated with an increased risk of breast cancer - the PGR-12 (rs1042638) V660L valine to leucine polymorphism [VL heterozygotes (odds ratio, 1.13; 95% confidence interval, 1.03-1.24) and the LL homozygotes (odds ratio, 1.30; 95% confidence interval, 0.98-1.73), P(het) = 0.008, P(trend) = 0.002].
  • We conclude that the 660L allele may be associated with a moderately increased risk of breast cancer, but that other common SNPs in the PGR gene are unlikely to be associated with a substantial risk of breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide / genetics. Receptors, Progesterone / genetics. Sequence Tagged Sites
  • [MeSH-minor] Aged. Case-Control Studies. Female. Gene Frequency. Great Britain. Haplotypes. Humans. Linkage Disequilibrium. Middle Aged. Risk. Valine / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Valine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614108.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Progesterone; HG18B9YRS7 / Valine
  •  go-up   go-down


33. Bailly JY, Amici JM, Guillot P: [Intralabial rotation flaps]. Ann Dermatol Venereol; 2005 Dec;132(12 Pt 1):1032-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lambeau de rotation intralabial.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Lip / surgery. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446657.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I: Pharmacological treatments for basal cell carcinoma. Drugs; 2007;67(6):915-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological treatments for basal cell carcinoma.
  • Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer, and its incidence continues to rise.
  • Several prospective, randomised, double-blind, vehicle-controlled studies have established the efficacy of imiquimod for superficial BCC.
  • Experimental treatments that have been successfully utilised in the treatment of BCC are also discussed.
  • Treatment of BCC with other agents, such as tazarotene, glycoalkaloid (BEC-5) cream, cidofovir and calcium dobesilate have been reported, but further studies are needed to ascertain the efficacy and adverse-effect profiles of these treatments.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2006-11 [10473079.001]
  • [Cites] Lasers Surg Med. 1990;10(5):485-8 [2146455.001]
  • [Cites] Gen Pharmacol. 1998 Sep;31(3):357-60 [9703201.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] Prim Care Update Ob Gyns. 1998 Jul 1;5(4):151 [10838279.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10 ):1325-32 [14568837.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):477-8 [15338000.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2908-11 [8674038.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1490-5 [15611427.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Arch Dermatol. 1990 Aug;126(8):1029-32 [2383027.001]
  • [Cites] Arch Dermatol. 1983 Jan;119(1):44-50 [6849564.001]
  • [Cites] Br J Dermatol. 2003 Feb;148(2):195-202 [12588368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1347-50 [7635774.001]
  • [Cites] J Dermatol. 1996 Jun;23 (6):394-6 [8708151.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):605-8 [8123497.001]
  • [Cites] Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents [11585785.001]
  • [Cites] J Dermatol Surg Oncol. 1992 Jul;18(7):549-54 [1624628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):406-11 [15380573.001]
  • [Cites] Mol Carcinog. 2003 Sep;38(1):33-9 [12949841.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):562-4 [12459528.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Aug;55(2):143-52 [15886010.001]
  • [Cites] Australas J Dermatol. 2006 Feb;47(1):46-8 [16405483.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):258-65 [17034468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8 [9861020.001]
  • [Cites] J Am Acad Dermatol. 1993 Jan;28(1):17-21 [8318069.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):493-7 [12372093.001]
  • [Cites] Br J Plast Surg. 1995 Sep;48(6):360-70 [7551508.001]
  • [Cites] Cancer. 1997 Jun 15;79(12 ):2282-308 [9191516.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):452-7 [16112352.001]
  • [Cites] Nat Rev Immunol. 2001 Nov;1(2):135-45 [11905821.001]
  • [Cites] Histopathology. 1998 May;32(5):393-8 [9639112.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1603-8 [10188913.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):596-9 [9344200.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Arch Dermatol. 1985 Feb;121(2):207-13 [3977335.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1767-8 [10610445.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):907-10 [8959949.001]
  • [Cites] Curr Opin Immunol. 1998 Jun;10(3):271-8 [9638363.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2134-7 [1913451.001]
  • [Cites] Br J Ophthalmol. 1991 Jul;75(7):407-10 [1854693.001]
  • [Cites] J Dermatol. 2000 Jan;27(1):10-5 [10692817.001]
  • [Cites] Plast Reconstr Surg. 2000 Jun;105(7):2544-51 [10845311.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] Dermatologica. 1970;140:Suppl 1:47-54 [5471361.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 2):905-8 [2335582.001]
  • [Cites] Arch Dermatol. 1978 Jul;114(7):1021-2 [686718.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] J Interferon Cytokine Res. 1999 Aug;19(8):817-28 [10476925.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Med Lett Drugs Ther. 2004 Nov 8;46(1195):92 [15534568.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 2):S6-11 [10861101.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Int J Dermatol. 1998 Dec;37(12):881-96 [9888327.001]
  • [Cites] Br J Pharmacol. 1997 Dec;122(7):1502-8 [9421302.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):616-8 [9475772.001]
  • [Cites] J Photochem Photobiol B. 2000 Jan;54(1):72-80 [10739146.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] J Dermatol. 1993 Aug;20(8):507-13 [8245314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):235-42 [2394605.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Arch Dermatol Res. 2004 Jun;296(1):6-11 [15083310.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):32-4 [10025376.001]
  • [Cites] J Control Release. 2000 Apr 3;65(3):359-66 [10699294.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:15-22 [14522637.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):587-93 [9808527.001]
  • [Cites] Immunity. 2001 Jun;14(6):661-4 [11420036.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Plast Reconstr Surg. 1988 Dec;82(6):1067-71 [3059383.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):443-56 [8445672.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):739-42 [646395.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):338-40 [10759821.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):301-16 [15134506.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):181-91 [16831473.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Arch Dermatol. 1995 Jun;131(6):737-8 [7778936.001]
  • [Cites] Dermatol Surg. 2006 Jan;32(1):63-9 [16393600.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4289-94 [12154031.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1757-63 [2407343.001]
  • [Cites] N Z Med J. 2005 Oct 07;118(1223):U1682 [16224506.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1462-9 [15606733.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2151-6 [11929837.001]
  • [Cites] Recent Results Cancer Res. 2002;160:246-50 [12079220.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4746-56 [8648121.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):135-41 [10620129.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4334-42 [10485481.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):248-9 [9487227.001]
  • [Cites] J Am Acad Dermatol. 1981 Jun;4(6):633-49 [7016939.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Med Res. 2001 Jul-Aug;32(4):273-6 [11440782.001]
  • [Cites] Arch Dermatol. 1992 Dec;128(12):1597-601 [1456752.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S [9305675.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Photochem Photobiol. 2000 Jun;71(6):724-9 [10857368.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3904-9 [9307269.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):318-23 [15841634.001]
  • [Cites] Int J Cardiol. 1995 May;49(3):282-3 [7649677.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Antiviral Res. 1999 Aug;43(1):55-63 [10480263.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1608-17 [14647422.001]
  • [Cites] J Am Acad Dermatol. 2000 Mar;42(3):389-413; quiz 414-6 [10688709.001]
  • [Cites] J Photochem Photobiol B. 2001 Apr;60(1):37-43 [11386679.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Arch Dermatol. 2003 Sep;139(9):1173-7 [12975159.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):526-7 [16112368.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1167-8 [2273122.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3249-59 [10955811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):748-55 [11697321.001]
  • [Cites] J Dermatol Surg Oncol. 1992 Jun;18(6):471-6 [1592998.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23 (4 Pt 1):694-700 [2229497.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):140-1 [16309513.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23 (34):8835-44 [16314644.001]
  • [Cites] Br J Pharmacol. 2003 Jun;139(4):854-62 [12813009.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Dermatology. 1995;190(3):214-7 [7599384.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] Br J Dermatol. 2004 Sep;151(3):656-62 [15377354.001]
  • [Cites] Arch Dermatol. 1991 Nov;127(11):1668-72 [1952970.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] Photochem Photobiol Sci. 2002 Jan;1(1):1-21 [12659143.001]
  • (PMID = 17428108.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  • [Number-of-references] 167
  •  go-up   go-down


35. Mays MC: Basaloid epithelial tumors of dogs and cats. Vet Clin Pathol; 2010 Jun;39(2):133; author reply 133-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid epithelial tumors of dogs and cats.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Vet Clin Pathol. 2010 Mar;39(1):96-8 [19645743.001]
  • (PMID = 20624263.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Yu Y, Wu JK, Malek AM, Finn DT: An intracranial dural arteriovenous fistula found during a dermatologic examination. Arch Dermatol; 2010 Jul;146(7):808-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arteriovenous Fistula / diagnosis. Carcinoma, Basal Cell / diagnosis. Intracranial Arteriovenous Malformations / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Angiography / methods. Biopsy. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644056.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


37. Papadopoulos O, Chrisostomidis C, Karypidis D, Champsas G, Konofaos P: Reuse of the same facial flap. Br J Oral Maxillofac Surg; 2008 Jan;46(1):81-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Hemangioma, Cavernous / surgery. Neoplasms, Second Primary / surgery. Nose Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Face / surgery. Female. Humans. Middle Aged. Reconstructive Surgical Procedures / methods. Skin Transplantation. Subcutaneous Tissue / transplantation

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706846.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  •  go-up   go-down


38. Albrektsen G, Heuch I, Thoresen SØ: Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC Cancer; 2010;10:226
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway.
  • BACKGROUND: Some studies have indicated that reproductive factors affect the risk of histological types of breast cancer differently.
  • The long-term protective effect of a childbirth is preceded by a short-term adverse effect.
  • METHODS: In the present register-based study, comprising information for 22,867 Norwegian breast cancer cases (20-74 years), we examined whether histological type (9 categories) and grade of tumor (2 combined categories) differed by parity or age at first birth.
  • RESULTS: Ductal tumors, the most common histological type, accounted for 81.4% of all cases, followed by lobular tumors (6.3%) and unspecified carcinomas (5.5%).
  • Other subtypes accounted for 0.4%-1.5% of the cases each.
  • The proportion of mucinous and tubular tumors decreased with increasing parity, whereas Paget disease and medullary tumors were most common in women of high parity.
  • An increasing trend with increasing age at first birth was most pronounced for lobular tumors and unspecified carcinomas; an association in the opposite direction was seen in relation to medullary and tubular tumors.
  • In age-adjusted analyses, only the proportions of unspecified carcinomas and lobular tumors decreased significantly with increasing time since first and last birth.
  • However, ductal tumors, and malignant sarcomas, mainly phyllodes tumors, seemed to occur at higher frequency in women diagnosed <2 years after first childbirth.
  • The proportions of medullary tumors and Paget disease were particularly high among women diagnosed 2-5 years after last birth.
  • CONCLUSION: Our results support previous observations that reproductive factors affect the risk of histological types of breast cancer differently.
  • Sarcomas, medullary tumors, and possible also Paget disease, may be particularly susceptible to pregnancy-related exposure.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Maternal Age. Parity
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Chi-Square Distribution. Female. Humans. Logistic Models. Middle Aged. Neoplasm Staging. Norway / epidemiology. Odds Ratio. Paget's Disease, Mammary / etiology. Paget's Disease, Mammary / pathology. Pregnancy. Registries. Risk Assessment. Risk Factors. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1995 Dec;31A(13-14):2289-95 [8652258.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3427-34 [19064558.001]
  • [Cites] Lancet. 1997 May 24;349(9064):1505-10 [9167459.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):49-55 [10077152.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):167-75 [15597097.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):364-71 [16079783.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):655-61 [15929077.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1046-52 [16175185.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):65-9 [16434588.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):608-20 [16436674.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R11 [16507159.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1050-6 [10574602.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):293-300 [11114708.001]
  • [Cites] J Surg Oncol. 2001 Jul;77(3):171-8 [11455553.001]
  • [Cites] J Am Coll Surg. 2002 Jan;194(1):54-64 [11800340.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):235-41 [11895871.001]
  • [Cites] Cancer Causes Control. 2002 May;13(4):295-8 [12074498.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):91-8; discussion 99 [12511159.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1055-60 [12942575.001]
  • [Cites] Breast. 2003 Dec;12(6):516-21 [14659129.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):699-705 [14966094.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):102-9 [15054874.001]
  • [Cites] Obstet Gynecol. 2004 Jul;104(1):146-54 [15229014.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1263-8 [15365566.001]
  • [Cites] South Med J. 1980 Jan;73(1):28-32 [6243191.001]
  • [Cites] Cancer. 1984 Feb 1;53(3 Suppl):623-9 [6318954.001]
  • [Cites] Acta Oncol. 1987;26(5):343-8 [3426845.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):147-53 [8380113.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):23-34 [7999466.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):413-9 [8635853.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):946-54 [16702375.001]
  • [Cites] Breast Dis. 2005-2006;23:9-15 [16823162.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1468-74 [16642468.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1448-58 [16933329.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1899-905 [17035397.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):910-8 [17081916.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):71-82 [17318269.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):127-35 [17330844.001]
  • [Cites] World J Surg Oncol. 2007;5:57 [17540032.001]
  • [Cites] Am Surg. 2007 Oct;73(10):967-9 [17983058.001]
  • [Cites] Breast J. 2007 Nov-Dec;13(6):620-1 [17983410.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):730-6 [17932112.001]
  • [Cites] Radiographics. 2007 Oct;27 Suppl 1:S101-24 [18180221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):710-3 [18234448.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R41 [18466608.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):215-23 [18789610.001]
  • [Cites] Cancer Lett. 2008 Dec 18;272(2):206-20 [18842336.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):538-44 [19190634.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):751-5 [8824544.001]
  • (PMID = 20492657.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2889893
  •  go-up   go-down


39. Ben Slama L: [Carcinoma of the lips]. Rev Stomatol Chir Maxillofac; 2009 Nov;110(5):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the lips].
  • Epidermoid carcinoma, that is, squamous cell carcinoma of the skin, is the most common malignant tumor of the lips.
  • Epidermoid carcinoma may appear clinically as a scaly erosion or an ulceration.
  • [MeSH-minor] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Humans. Leukoplakia, Oral / pathology. Smoking / adverse effects. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361830.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


40. Kocharin K, Rachathewee P, Sanglier JJ, Prathumpai W: Exobiopolymer production of Ophiocordyceps dipterigena BCC 2073: optimization, production in bioreactor and characterization. BMC Biotechnol; 2010;10:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exobiopolymer production of Ophiocordyceps dipterigena BCC 2073: optimization, production in bioreactor and characterization.
  • The ascomycetous fungus Ophiocordyceps dipterigena BCC 2073 produces an exobiopolymer, a (1-->3)-beta-D-glucan, in low quantity under screening conditions.
  • Optimization of O. dipterigena BCC 2073 exobiopolymer production using experimental designs, a scale-up in 5 liter bioreactor, analysis of molecular weight at different cultivation times, and levels of induction of interleukin-8 synthesis are described in this study.
  • CONCLUSIONS: High exobiopolymer yield produced by O. dipterigena BCC 2073 after optimization by qualitative and quantitative methods is attractive for various applications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Lett. 2001 Jan 1;194(1):65-9 [11150667.001]
  • [Cites] Bioresour Technol. 2008 May;99(8):3187-94 [17624770.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Jul;56(1-2):88-92 [11499951.001]
  • [Cites] Lett Appl Microbiol. 2002;34(1):56-61 [11849494.001]
  • [Cites] Lett Appl Microbiol. 2002;34(6):389-93 [12028416.001]
  • [Cites] Lett Appl Microbiol. 2002;34(6):433-8 [12028425.001]
  • [Cites] J Appl Microbiol. 2003;94(1):120-6 [12492932.001]
  • [Cites] Biotechnol Prog. 2003 Mar-Apr;19(2):428-35 [12675583.001]
  • [Cites] Lett Appl Microbiol. 2003;36(5):321-6 [12680946.001]
  • [Cites] Appl Microbiol. 1971 Oct;22(4):641-9 [5167099.001]
  • [Cites] Carbohydr Res. 1979 Nov;76:277-80 [526958.001]
  • [Cites] Enzyme Microb Technol. 1996 Sep;19(4):261-6 [8987486.001]
  • [Cites] Crit Rev Biotechnol. 1997;17(4):327-61 [9397533.001]
  • [Cites] Trends Biotechnol. 1998 Jan;16(1):41-6 [9470230.001]
  • [Cites] Int J Biol Macromol. 1999 Jan;24(1):61-4 [10077273.001]
  • [Cites] J Biotechnol. 2005 Mar 2;116(1):61-77 [15652430.001]
  • [Cites] Lett Appl Microbiol. 2006 May;42(5):501-6 [16620210.001]
  • [Cites] Appl Biochem Biotechnol. 2006 Sep;134(3):249-62 [16960283.001]
  • [Cites] Lett Appl Microbiol. 2001 Jul;33(1):76-81 [11442820.001]
  • (PMID = 20624309.001).
  • [ISSN] 1472-6750
  • [Journal-full-title] BMC biotechnology
  • [ISO-abbreviation] BMC Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biopolymers; 0 / Interleukin-8
  • [Other-IDs] NLM/ PMC2912784
  •  go-up   go-down


41. Balasundram S, Kovilpillai FJ, Hopper C: Nevoid basal cell carcinoma syndrome presenting with neck pits and café au lait patches. J Clin Pediatr Dent; 2010;35(1):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome presenting with neck pits and café au lait patches.
  • RESULTS: Clinical examination also revealed macrocephaly, fronto-parietal bossing, pitting on palmar and plantar surfaces, calcification of falx cerebri and splayed ribs, confirming the diagnosis of nevoid basal cell carcinoma syndrome.
  • He also presented with a cafi au lait patch and skin pits on the neck.
  • The family history was negative for features of nevoid basal cell carcinoma syndrome.
  • CONCLUSION: Nevoid basal cell carcinoma syndrome is a condition that can cause significant morbidity if not detected early.
  • Over the years this syndrome has presented with many other non specific phenotype presentation, of which the current finding may be one of This calls for meticulous assessment and examination of patients and a standardized protocol in screening and managing these patients that may facilitate a more beneficial outcome for the patient.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Cafe-au-Lait Spots / diagnosis. Neck / pathology. Skin Abnormalities / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Mandibular Diseases / diagnosis. Maxillary Diseases / diagnosis. Odontogenic Cysts / diagnosis. Recurrence. Ribs / abnormalities

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189772.001).
  • [ISSN] 1053-4628
  • [Journal-full-title] The Journal of clinical pediatric dentistry
  • [ISO-abbreviation] J Clin Pediatr Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Wu JK, Oh C, Strutton G, Siller G: An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol; 2006 Feb;47(1):46-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
  • SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established.
  • This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs.
  • Curettage was used to de-bulk the lesion and confirm suitable histology.
  • Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma.
  • Curettage followed by imiquimod 5% cream is effective for the treatment of primary nodular basal cell carcinoma on the trunk and limbs, and most patients are pleased with the cosmetic outcome.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Curettage / methods. Emollients / therapeutic use. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Risk Assessment. Single-Blind Method. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405483.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Emollients; 99011-02-6 / imiquimod
  •  go-up   go-down


43. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Fukuoka H, Moriuchi M, Yano H, Nagayasu T, Moriuchi H: No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer. J Med Virol; 2008 Aug;80(8):1447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer.
  • Mouse mammary tumor virus (MMTV) is the causative agent of breast tumors in mice.
  • Recently, DNA sequences homologous or closely related to MMTV env gene have been specifically detected in breast cancer tissue from significant numbers of American, Australian, and Tunisian women, suggesting a viral etiology for at least a part of human breast cancer.
  • However, the viral sequences have not been detected from any of breast cancer samples in several subsequent studies.
  • Thus, whether MMTV-related retrovirus is a causative agent of human breast cancer remains controversial.
  • To demonstrate if MMTV-related retrovirus is involved in Japanese cases of breast cancer, breast tissue specimens from 46 breast cancer patients and 3 patients with benign mammary tumors were investigated.
  • Thus, MMTV itself or MMTV-related retrovirus is not associated with breast carcinogenesis in Japanese women, and it is unclear whether this conclusion is merely a reflection of regional differences in its epidemics.
  • [MeSH-major] Breast Neoplasms. Gene Products, env / genetics. Genes, env. Mammary Tumor Virus, Mouse / isolation & purification
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / virology. Adult. Aged. Aged, 80 and over. Animals. Blotting, Southern. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / virology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / virology. Cell Line, Tumor. Female. Fibroadenoma / epidemiology. Fibroadenoma / genetics. Fibroadenoma / virology. Humans. Japan / epidemiology. Mice. Middle Aged. Nucleic Acid Hybridization. Phyllodes Tumor / epidemiology. Phyllodes Tumor / genetics. Phyllodes Tumor / virology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551605.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env
  •  go-up   go-down


45. Dierks C: GDC-0449--targeting the hedgehog signaling pathway. Recent Results Cancer Res; 2010;184:235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was successfully tested in a phase-I clinical trial demonstrating good pharmacodynamic (PD) and pharmacokinetic (PK) properties and showing objective response and clinical benefit in several patients with basal cell carcinoma.
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / drug therapy. Clinical Trials as Topic. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20072843.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anilides; 0 / Antineoplastic Agents; 0 / HhAntag691; 0 / Pyridines; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human
  • [Number-of-references] 19
  •  go-up   go-down


46. Han J, Colditz GA, Liu JS, Hunter DJ: Genetic variation in XPD, sun exposure, and risk of skin cancer. Cancer Epidemiol Biomarkers Prev; 2005 Jun;14(6):1539-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in XPD, sun exposure, and risk of skin cancer.
  • We assessed the associations between two common nonsynonymous polymorphisms (Asp312Asn and Lys751Gln) with skin cancer risk in a nested case-control study within the Nurses' Health Study (219 melanoma, 286 squamous cell carcinoma, 300 basal cell carcinoma, and 874 controls) along with exploratory analysis on the haplotype structure of the XPD gene.
  • There were inverse associations between the Lys751Gln and Asp312Asn polymorphisms and the risks of melanoma and squamous cell carcinoma.
  • No association was observed between these two polymorphisms and basal cell carcinoma risk.
  • Our data suggest these two XPD nonsynonymous polymorphisms may be associated with skin cancer risk, especially for melanoma.
  • [MeSH-major] DNA Helicases / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Skin Neoplasms / etiology. Sunlight / adverse effects. Transcription Factors / genetics
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Case-Control Studies. DNA Repair. Female. Genetic Predisposition to Disease. Haplotypes. Humans. Melanoma / etiology. Middle Aged. Risk Factors. Xeroderma Pigmentosum Group D Protein

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941969.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA97746
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


47. Garvey C, Garvey K, Hendi A: A review of common dermatologic disorders of the external ear. J Am Acad Audiol; 2008 Mar;19(3):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin disorders of the external ear are common.
  • This report summarizes eight of the most commonly encountered skin conditions with an emphasis on recognition and appropriate referral.
  • The cutaneous disorders of the external ear discussed in the article are divided into benign, premalignant, and malignant groups.
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Malassezia / isolation & purification. Melanoma / pathology. Photosensitivity Disorders / microbiology. Photosensitivity Disorders / pathology. Pruritus / diagnosis. Pruritus / etiology. Psoriasis / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672650.001).
  • [ISSN] 1050-0545
  • [Journal-full-title] Journal of the American Academy of Audiology
  • [ISO-abbreviation] J Am Acad Audiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 10
  •  go-up   go-down


48. Gallagher RP, Lee TK: Adverse effects of ultraviolet radiation: a brief review. Prog Biophys Mol Biol; 2006 Sep;92(1):119-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • UVR is a known carcinogen and excessive exposure-at least to solar radiation in sunlight-increases risk of cancer of the lip, basal cell, and squamous cell carcinoma of the skin and cutaneous melanoma, particularly in fair skin populations.
  • Artificial UVR from tanning beds, welding torches, and other sources, may contribute to the burden of disease from UVR.
  • This brief review will assess the human evidence for adverse health effects from solar and artificial UVR and will attempt to assign a degree of certainty to the major disease-exposure relationships based on the weight of available scientific evidence.
  • [MeSH-major] Environmental Exposure / statistics & numerical data. Eye Diseases / mortality. Radiation Injuries / mortality. Risk Assessment / methods. Skin Diseases / mortality. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580054.001).
  • [ISSN] 0079-6107
  • [Journal-full-title] Progress in biophysics and molecular biology
  • [ISO-abbreviation] Prog. Biophys. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 130
  •  go-up   go-down


49. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG: Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol; 2006 Dec;155(6):1154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
  • BACKGROUND: Extensive exposure to ultraviolet radiation is associated with genetic alterations in basal cell carcinomas (BCCs), which represent some 75% of skin cancers.
  • OBJECTIVES: As recent data suggested the fragile histidine triad (FHIT) gene product to participate in DNA damage responses we wished to address whether functional deletion of this tumour suppressor participates in the development of BCC.
  • METHODS: Paraffin-embedded specimens from 17 patients with BCC were available for methylation-specific polymerase chain reaction (MSP), combined bisulphite-dependent restriction analysis (COBRA) of the FHIT gene and immunohistochemistry of its product.
  • RESULTS: We report for the first time that 100% of BCCs are negative for FHIT by immunostaining.
  • Aberrant methylation of the FHIT promoter occurred in a significant portion of BCCs.
  • MSP detected hypermethylation of the FHIT/FRA3B locus in nine of nine (100%) periocular BCCs and in six of eight (75%) BCCs from other body regions.
  • COBRA yielded similar results, confirming that some 88% of the 17 BCCs analysed harbour epigenetic silencing of the FHIT gene.
  • CONCLUSIONS: We have identified epigenetic silencing of the FHIT tumour suppressor gene as a frequent inactivation mechanism which is likely to contribute to functional deficiencies in DNA damage response of BCCs.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Carcinoma, Basal Cell / genetics. Gene Silencing. Genes, Tumor Suppressor. Neoplasm Proteins / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107382.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


50. Low JA, de Sauvage FJ: Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol; 2010 Dec 20;28(36):5321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hedgehog (Hh) signaling pathway is critical for cell growth and differentiation during embryogenesis and early development.
  • While it is mostly quiescent in adults, inappropriate reactivation of the Hh pathway has been shown to be involved in the development of cancer.
  • Alternatively, Hh ligands may act on cancer stem cells in some hematopoietic cancers, such as chronic myelogenous leukemia.
  • However, the role of the Hh pathway is best established in tumors, such as basal cell carcinoma and medulloblastoma, where the pathway is activated via mutations.
  • [MeSH-major] Anilides / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Pyridines / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21041712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / HhAntag691; 0 / Pyridines; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human
  •  go-up   go-down


51. Peitsch WK, Hofmann I, Bulkescher J, Hergt M, Spring H, Bleyl U, Goerdt S, Franke WW: Drebrin, an actin-binding, cell-type characteristic protein: induction and localization in epithelial skin tumors and cultured keratinocytes. J Invest Dermatol; 2005 Oct;125(4):761-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drebrin, an actin-binding, cell-type characteristic protein: induction and localization in epithelial skin tumors and cultured keratinocytes.
  • Isoform E2 of drebrin, an actin-binding protein originally identified in neuronal cells, has recently been identified in diverse non-neuronal cells, mostly in association with cell processes and intercellular junctions.
  • Here, we report on the presence of drebrin in normal human skin, epithelial skin cancers, and cultured keratinocytes.
  • By immunohistochemistry and immunoblot, basal cell carcinomas (BCC) are rich in drebrin, and confocal laser scanning and immunoelectron microscopy show accumulation at adhering junctions, in co-localization with actin and partially with plaque proteins.
  • In squamous cell carcinomas, keratoacanthomas, and in epidermal precancers, drebrin is heterogeneously distributed, appearing as mosaics.
  • When epithelium-derived cells devoid of drebrin are transfected with drebrin-enhanced green fluorescent protein, constructs accumulate in the cell periphery, and immunoprecipitation shows complexes with actin.
  • During epidermal growth factor induced formation of cell processes, drebrin retains this junction association, as observed by live cell microscopy.
  • Our results suggest novel functions of drebrin such as an involvement in cell-cell adhesion and tumorigenesis and a potential value in diagnosis of BCC.
  • [MeSH-major] Keratinocytes / metabolism. Microfilament Proteins / analysis. Neoplasms, Glandular and Epithelial / chemistry. Neuropeptides / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Female. Fluorescent Antibody Technique. Humans. Immunoblotting. Microscopy, Confocal. Microscopy, Immunoelectron. Skin / chemistry. Transfection

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185277.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Neuropeptides; 0 / drebrin E; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


52. Herrero JI, España A, Quiroga J, Sangro B, Pardo F, Alvárez-Cienfuegos J, Prieto J: Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl; 2005 Sep;11(9):1100-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmelanoma skin cancer after liver transplantation. Study of risk factors.
  • Nonmelanoma skin cancer (NMSC) is a frequent complication after liver transplantation, but the risk factors of posttransplant NMSC have not been well defined.
  • In univariate analysis, older age, male sex, Child-Turcotte-Pugh A or B at transplantation, treatment with mycophenolate mofetil, skin type, and total pretransplant sun burden were associated to the development of NMSC.
  • In multivariate analysis, only skin type and total sun burden were independently related to NMSC.
  • In conclusion, risk of posttransplant NMSC may be estimated combining skin type and an easy estimation of total sun burden.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Liver Transplantation / adverse effects. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123952.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


53. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB, Miller WR: The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol; 2005 May;95(1-5):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
  • Intratumoral aromatase is a therapeutic target for the treatment of post-menopausal estrogen-dependent breast cancers.
  • With these two monoclonal antibodies 43 cases of invasive ductal carcinoma, which had been previously assayed for aromatase activity by product isolation methodology, were immunostained in three laboratories in UK, USA and Japan and independently evaluated by three pathologists (H.S., T.A. and S.G.S.).
  • Staining of malignant epithelium, adipose tissue, normal/benign and stromal compartments of the tumors were assessed by estimating the proportion of positive staining cells and the relative intensity of staining in this fashion.
  • Immunoreactivity could be detected in each component of the tissue specimens but a significant positive correlation with biochemical activity was detected only in malignant epithelium stained with 677 not in other components with #677 and not in any of the components.
  • A methodology and scoring system is recommended whereby staining significantly correlates with aromatase activity of the resected tissue specimens of breast cancer.
  • [MeSH-major] Antibodies, Monoclonal. Aromatase / analysis. Breast Neoplasms / enzymology. Immunohistochemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024247.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


54. Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Waltes R, Bremer M, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Humphreys K, Liu J, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, kConFab Investigators, AOCS Group, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U, GENICA Consortium, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benítez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J, Breast Cancer Association Consortium: Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev; 2010 Sep;19(9):2143-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.
  • BACKGROUND: Truncating mutations in ATM have been shown to increase the risk of breast cancer but the effect of missense variants remains contentious.
  • METHODS: We have genotyped five polymorphic (minor allele frequency, 0.9-2.6%) missense single nucleotide polymorphisms (SNP) in ATM (S49C, S707P, F858L, P1054R, and L1420F) in 26,101 breast cancer cases and 29,842 controls from 23 studies in the Breast Cancer Association Consortium.
  • The trend OR among bilateral and familial cases was 1.12 (95% confidence interval, 1.02-1.23; P(trend) = 0.02).
  • CONCLUSIONS: In this large combined analysis, these five missense ATM SNPs were associated with a small increased risk of breast cancer, explaining an estimated 0.03% of the excess familial risk of breast cancer.
  • IMPACT: Testing the combined effects of rare missense variants in known breast cancer genes in large collaborative studies should clarify their overall contribution to breast cancer susceptibility.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Mutation, Missense. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Case-Control Studies. DNA Mutational Analysis. Female. Genetic Predisposition to Disease. Genotype. Humans. Polymorphism, Single Nucleotide. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Mol Genet Metab. 1999 Dec;68(4):419-23 [10607471.001]
  • [Cites] Am J Hum Genet. 2009 Oct;85(4):427-46 [19781682.001]
  • [Cites] Breast Cancer Res. 2002;4(6):R15 [12473176.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):733-8 [12917204.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Genet Epidemiol. 2003 Nov;25(3):190-202 [14557987.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):109-19 [15101044.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1242-50 [9333265.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):247-62 [15557798.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • [Cites] Hum Mutat. 2006 Jun;27(6):538-44 [16652348.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 19;98(14):1014-8 [16849685.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):873-5 [16832357.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5906-11 [16998505.001]
  • [Cites] Hum Mutat. 2006 Nov;27(11):1122-8 [16958054.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1239-41 [17033622.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):352-8 [17293864.001]
  • [Cites] Hum Mol Genet. 2007 May 1;16(9):1051-7 [17341484.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):865-9 [17529974.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Nov;39(11):1329-37 [17952073.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):243-8 [17393301.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):703-6 [18438407.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6486-91 [18701470.001]
  • [Cites] Hum Mutat. 2008 Nov;29(11):1261-4 [18951436.001]
  • [Cites] Hum Mutat. 2008 Nov;29(11):1265-72 [18951437.001]
  • [Cites] Hum Mutat. 2008 Nov;29(11):1327-36 [18951440.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):95-107 [19165225.001]
  • [Cites] Nat Genet. 2009 Mar;41(3):324-8 [19219042.001]
  • [Cites] Nat Rev Genet. 2009 Apr;10(4):241-51 [19293820.001]
  • [Cites] Nat Genet. 2009 May;41(5):579-84 [19330030.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7608-15 [11606401.001]
  • (PMID = 20826828.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA069417; United States / NCI NIH HHS / CA / U01 CA069638; United States / NCI NIH HHS / CA / R01 CA122340-03S1; United States / NCI NIH HHS / CA / CA116201; United States / NCI NIH HHS / CA / CA128978; United States / NCI NIH HHS / CA / R01 CA128978-03; United States / NCI NIH HHS / CA / R01 CA122340-02; United States / NCI NIH HHS / CA / CA69631; United Kingdom / Cancer Research UK / / C1287/A7497; United Kingdom / Cancer Research UK / / A10118; United States / NCI NIH HHS / CA / U01 CA069467; United States / NCI NIH HHS / CA / CA69467; United States / NCI NIH HHS / CA / R01 CA128978-01A2; United States / NCI NIH HHS / CA / P50 CA116201-010005; United States / NCI NIH HHS / CA / R01 CA058860; United States / NCI NIH HHS / CA / CA122340; United States / NCI NIH HHS / CA / U01 CA069398; United States / NCI NIH HHS / CA / CA102740-01A2; United States / NCI NIH HHS / CA / R01 CA122340-03; United Kingdom / Cancer Research UK / / C8197/A10865; United States / NCI NIH HHS / CA / R01 CA128978; United States / NCI NIH HHS / CA / R01 CA128978-02; United States / NCI NIH HHS / CA / CA69417; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / R01 CA122340-05; United Kingdom / Cancer Research UK / / 11021; United States / NCI NIH HHS / CA / R01 CA122340-04; United States / NCI NIH HHS / CA / P50 CA116201-020005; United States / NCI NIH HHS / CA / U01 CA069631; United States / NCI NIH HHS / CA / R01 CA058860-11; United States / NCI NIH HHS / CA / CA69638; United States / NCI NIH HHS / CA / U01 CA058860; United Kingdom / Cancer Research UK / / A5260; United Kingdom / Cancer Research UK / / A5660; United States / NCI NIH HHS / CA / CA69398; United States / NCI NIH HHS / CA / P50 CA116201-030005; United States / NCI NIH HHS / CA / CA-95-011; United States / NCI NIH HHS / CA / R01 CA122340; United Kingdom / Cancer Research UK / / C1287/A10118; United States / NCI NIH HHS / CA / CA-58860; United States / NCI NIH HHS / CA / U01 CA069446; United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / A4343; United Kingdom / Cancer Research UK / / A10124; United Kingdom / Cancer Research UK / / C490/A11021; United States / NCI NIH HHS / CA / R01 CA128978-04; United Kingdom / Cancer Research UK / / A7497; United States / NCI NIH HHS / CA / R01 CA102740; United Kingdom / Cancer Research UK / / 10124; United States / NCI NIH HHS / CA / CA69446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS219781; NLM/ PMC2938473
  • [Investigator] D Bowtell; G Chenevix-Trench; A de Fazio; D Gertig; A Green; P Webb
  •  go-up   go-down


55. Menard A, de Los Santos PE, Graindorge A, Cournoyer B: Architecture of Burkholderia cepacia complex sigma70 gene family: evidence of alternative primary and clade-specific factors, and genomic instability. BMC Genomics; 2007;8:308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Architecture of Burkholderia cepacia complex sigma70 gene family: evidence of alternative primary and clade-specific factors, and genomic instability.
  • BACKGROUND: The Burkholderia cepacia complex (Bcc) groups bacterial species with beneficial properties that can improve crop yields or remediate polluted sites but can also lead to dramatic human clinical outcomes among cystic fibrosis (CF) or immuno-compromised individuals.
  • Bcc genome-wide analyses were performed to investigate the major evolutionary trends taking place in the sigma70 family of these bacteria.
  • Some paralogs appeared limited to the ET12 epidemic clone (ecfA2), particular Bcc species (sigI), the Burkholderia genus (ecfJ, ecfF, and sigJ), certain proteobacterial groups (ecfA1, ecfC, ecfD, ecfE, ecfG, ecfL, ecfM and rpoS), or were broadly distributed in the eubacteria (ecfI, ecfK, ecfH, ecfB, and rpoD-, rpoH-, fliA-like genes).
  • CONCLUSION: The Bcc sigma70 gene family was found to be under strong selective pressures that could lead to acquisition/deletion, and duplication events modifying its architecture.
  • Comparative analysis of Bcc and Pseudomonas aeruginosa sigma70 gene families revealed distinct evolutionary strategies, with the Bcc having selected several alternative primary factors, something not recorded among P. aeruginosa and only previously reported to occur among the actinobacteria.
  • [MeSH-major] Burkholderia cepacia / genetics. DNA-Directed RNA Polymerases / genetics. Genes, Bacterial. Genomic Instability. Sigma Factor / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6 [11435245.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 15;24(22):4420-49 [8948633.001]
  • [Cites] Nature. 2002 May 9;417(6885):141-7 [12000953.001]
  • [Cites] FEMS Immunol Med Microbiol. 2002 Jun 3;33(2):143-9 [12052570.001]
  • [Cites] Environ Microbiol. 2002 Dec;4(12):842-55 [12534467.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1739-47 [12620866.001]
  • [Cites] Res Microbiol. 2003 Mar;154(2):91-6 [12648723.001]
  • [Cites] J Bacteriol. 2003 Dec;185(23):7008-14 [14617667.001]
  • [Cites] Genome Biol. 2004;5(2):R12 [14759262.001]
  • [Cites] Appl Environ Microbiol. 2004 Feb;70(2):991-8 [14766581.001]
  • [Cites] Int J Syst Evol Microbiol. 2004 May;54(Pt 3):689-91 [15143009.001]
  • [Cites] J Clin Microbiol. 1997 Apr;35(4):808-16 [9157133.001]
  • [Cites] J Mol Biol. 1997 Aug 22;271(3):386-404 [9268667.001]
  • [Cites] Int J Syst Bacteriol. 1997 Oct;47(4):1188-200 [9336927.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):2123-6 [9650981.001]
  • [Cites] J Mol Biol. 1998 Dec 18;284(5):1353-65 [9878355.001]
  • [Cites] J Bacteriol. 1999 Sep;181(17):5512-5 [10464229.001]
  • [Cites] Thorax. 2004 Nov;59(11):952-4 [15516470.001]
  • [Cites] J Bacteriol. 1951 Sep;62(3):293-300 [14888646.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D192-6 [15608175.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):144-56 [15643431.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1193-201 [15746318.001]
  • [Cites] Bioinformatics. 2005 Aug 15;21(16):3422-3 [15976072.001]
  • [Cites] Arch Microbiol. 2005 Nov;184(3):175-86 [16193283.001]
  • [Cites] Can J Microbiol. 2006 Mar;52(3):260-5 [16604122.001]
  • [Cites] J Bacteriol. 2006 May;188(10):3631-44 [16672617.001]
  • [Cites] J Med Microbiol. 2006 Jun;55(Pt 6):661-8 [16687582.001]
  • [Cites] Mol Microbiol. 2007 Apr;64(1):165-79 [17376080.001]
  • [Cites] Environ Microbiol. 2007 May;9(5):1176-85 [17472633.001]
  • [Cites] J Microbiol Methods. 2007 Jul;70(1):20-9 [17490767.001]
  • [Cites] Brief Bioinform. 2004 Jun;5(2):150-63 [15260895.001]
  • [Cites] J Bacteriol. 2000 Feb;182(3):637-46 [10633096.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1042-7 [10698993.001]
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1651-5 [10747161.001]
  • [Cites] Nucleic Acids Res. 2000 Sep 1;28(17):3278-88 [10954595.001]
  • [Cites] Nucleic Acids Res. 2000 Sep 15;28(18):3497-503 [10982868.001]
  • [Cites] Microbiology. 2000 Dec;146 Pt 12:3149-55 [11101673.001]
  • [Cites] Curr Opin Microbiol. 2001 Apr;4(2):145-51 [11282469.001]
  • [Cites] Genome Biol. 2000;1(6):REVIEWS0006 [11380986.001]
  • [Cites] Nucleic Acids Res. 1982 Sep 11;10(17):5303-18 [7145702.001]
  • [Cites] J Pediatr. 1984 Feb;104(2):206-10 [6420530.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] J Pediatr. 1988 Nov;113(5):859-62 [2903229.001]
  • [Cites] J Bacteriol. 1992 Jun;174(12):3843-9 [1597408.001]
  • [Cites] J Bacteriol. 1993 Feb;175(4):1153-64 [8432708.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Infect Dis. 1994 Dec;170(6):1616-21 [7996008.001]
  • [Cites] Mol Microbiol. 1995 Jul;17(1):37-48 [7476207.001]
  • [Cites] Biometals. 1995 Oct;8(4):309-17 [7580051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2790-4 [8610119.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):1-5 [11750686.001]
  • (PMID = 17784948.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sigma Factor; EC 2.7.7.- / RNA polymerase sigma 70; EC 2.7.7.6 / DNA-Directed RNA Polymerases
  • [Other-IDs] NLM/ PMC2194791
  •  go-up   go-down


56. Handisurya A, Gambhira R, Schellenbacher C, Shafti-Keramat S, Forslund O, Favre M, Kirnbauer R: Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol; 2009 Jan;90(Pt 1):136-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evidence of a possible association of cutaneous human papillomavirus (HPV) types, especially members of the genus Betapapillomavirus, and the development of non-melanoma skin cancer (NMSC) is accumulating.
  • This study examined the serological relationship between betapapillomavirus (beta-PV) types 5 and 8 and the new type HPV-92, which has recently been isolated from a basal cell carcinoma containing a high number of viral genomes.
  • If a close link to HPV infection can be conclusively established, these results may provide a basis for further evaluation of VLPs of beta-PVs as candidates for a prophylactic skin-type HPV vaccine, aimed at reducing the incidence of NMSC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):494-9 [8133532.001]
  • [Cites] J Invest Dermatol. 1995 Sep;105(3):367-71 [7665914.001]
  • [Cites] J Infect Dis. 1995 Dec;172(6):1584-7 [7594721.001]
  • [Cites] J Virol. 1996 May;70(5):3298-301 [8627814.001]
  • [Cites] J Invest Dermatol. 1997 May;108(5):712-5 [9129220.001]
  • [Cites] J Virol. 1998 Feb;72(2):959-64 [9444988.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):311-7 [9540967.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):696-701 [9764856.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1394-400 [15735026.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):98-107 [15982309.001]
  • [Cites] Methods Mol Med. 2005;119:445-62 [16350417.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2662-70 [16888028.001]
  • [Cites] Semin Immunol. 2006 Dec;18(6):362-74 [17011789.001]
  • [Cites] FEBS J. 2007 Apr;274(7):1747-58 [17313482.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Virol. 2007 Aug;81(16):8784-92 [17553881.001]
  • [Cites] J Infect Dis. 2007 Sep 15;196(6):876-83 [17703418.001]
  • [Cites] J Virol. 2008 Apr;82(8):3894-902 [18256157.001]
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):403-7 [10692096.001]
  • [Cites] J Virol. 2000 Dec;74(24):11636-41 [11090162.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] Vaccine. 2001 Feb 8;19(13-14):1783-93 [11166904.001]
  • [Cites] J Gen Virol. 2001 Nov;82(Pt 11):2799-804 [11602792.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):579-81 [12426567.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):52-6 [12807946.001]
  • [Cites] J Cutan Pathol. 2003 Aug;30(7):423-9 [12859739.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):64-73 [12890196.001]
  • [Cites] Virology. 2003 Aug 1;312(2):255-60 [12919731.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] J Invest Dermatol. 2004 Jun;122(6):1456-62 [15175037.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Virology. 1974 Aug;60(2):572-8 [4367495.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4 [1334560.001]
  • [Cites] J Virol. 1993 Dec;67(12):6929-36 [8230414.001]
  • (PMID = 19088282.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18990
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Capsid Proteins; 0 / HPV L1 protein, Human papillomavirus; 0 / Oncogene Proteins, Viral; 0 / Virosomes
  • [Other-IDs] NLM/ EMS55130; NLM/ PMC3795330
  •  go-up   go-down


57. Yamaguchi S, Funahashi H, Murakami T: Improved fertility in gilts and sows after artificial insemination of frozen-thawed boar semen by supplementation of semen extender with caffeine and CaCl2. J Reprod Dev; 2009 Dec;55(6):645-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In experiment 1, gilts were cervically inseminated twice with frozen-thawed boar spermatozoa (25 x 10(8) cells per dose) suspended in Modena solution (n=7) or modified Beltsville Thawing Solution supplemented with caffeine and CaCl(2) (BCC, n=7).
  • There was no difference in the total number of uterine PMNs between gilts inseminated with Modena solution and those inseminated with BCC (3.8 x 10(8) vs. 1.5 x 10(8) cells, respectively); however, the total number of uterine spermatozoa was higher when gilts were inseminated with BCC (40.6 x 10(6) cells) compared with those inseminated with Modena solution (1.4 x 10(6) cells, P<0.05).
  • In experiment 2, gilts and sows were subjected to intrauterine insemination twice with frozen-thawed spermatozoa suspended (25 x 10(8) sperm per dose) in Modena (n=21) or BCC (n=21).
  • The overall pregnancy and farrowing rates were higher in females inseminated with BCC (71.4 and 61.9%, respectively) compared with those inseminated with Modena solution (38.1 and 28.6%, respectively, P<0.05).
  • However, no significant difference in litter size of piglets was observed between treatments (7.2 +/- 1.6 piglets for Modena solution vs. 8.2 +/- 0.9 piglets for BCC solution).
  • In conclusion, we demonstrated that use of BCC solution for frozen-thawed boar semen produced better pregnancy and farrowing rates following AI than Modena solution, probably by reducing the phagocytosis of spermatozoa.
  • [MeSH-minor] Animal Husbandry / methods. Animal Husbandry / statistics & numerical data. Animals. Cell Survival / drug effects. Drug Synergism. Female. Fertilization / drug effects. Live Birth. Male. Oviducts / cytology. Oviducts / drug effects. Pregnancy. Pregnancy Rate. Sperm Transport / drug effects. Uterus / cytology. Uterus / drug effects. Uterus / immunology

  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CALCIUM CHLORIDE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734696.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cryoprotective Agents; 3G6A5W338E / Caffeine; M4I0D6VV5M / Calcium Chloride
  •  go-up   go-down


58. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgård R, Undén AB: Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol; 2006 Jan;208(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The naevoid basal cell carcinoma syndrome (NBCCS) is caused by mutations in the hedgehog receptor PTCH gene.
  • It is characterized by developmental defects and a predisposition to the development of certain tumours, such as basal cell carcinoma, medulloblastoma and meningioma, and potentially fetal rhabdomyomas and embryonal rhabdomyosarcomas.
  • This study aimed to analyse PTCH status in an NBCCS patient with fetal rhabdomyoma and to investigate whether deregulation of hedgehog signalling, as shown by altered expression of hedgehog pathway components and/or genetic imbalances, is a general finding in sporadic rhabdomyomas and rhabdomyosarcomas.
  • [MeSH-major] Receptors, Cell Surface / genetics. Repressor Proteins / genetics. Rhabdomyoma / genetics. Rhabdomyosarcoma / genetics. Signal Transduction / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / genetics. Child. Female. Gene Expression Regulation, Neoplastic / genetics. Genes, Neoplasm / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization. Infant. Loss of Heterozygosity / genetics. Male. Middle Aged. Mutation / genetics. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rhabdomyosarcoma, Embryonal / genetics. Submandibular Gland Neoplasms

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland.
  • (PMID = 16294371.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Repressor Proteins; 0 / SUFU protein, human; 0 / patched receptors
  •  go-up   go-down


59. Ninomiya J, Oyama T, Horiguchi J, Koibuchi Y, Yoshida T, Iijima K, Yoshida M, Takata D, Iino Y, Morishita Y: Two cases of breast cancer with cartilaginous and osseous metaplasia. Breast Cancer; 2005;12(1):52-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of breast cancer with cartilaginous and osseous metaplasia.
  • Invasive breast cancer (IBC) with cartilaginous or osseous metaplasia is rare.
  • Here we report two cases of this unusual variation.
  • Case 1: The patient was a 33-year-old woman with a right breast tumor, 2.2 cm in size.
  • Case 2: The patient was a 43-year-old woman with a left breast tumor, 4.2 cm in size.
  • A total adenectomy and lymph node dissection with breast reconstruction using a lattisimus dorsi muscle flap were performed.
  • Matrix producing carcinoma (MPC) has no intervening spindle cells and a better prognosis than other types, however, MPC has been reported to have the same prognosis as ordinary breast cancer after for adjusting its stage.
  • Our two cases were MPC's and no recurrence has been detected 5 and 3 years from the initial therapy, respectively.
  • [MeSH-major] Bone and Bones / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cartilage / pathology


60. Canzian F, Kaaks R, Cox DG, Henderson KD, Henderson BE, Berg C, Bingham S, Boeing H, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Dossus L, Feigelson HS, Haiman CA, Hankinson SE, Hoover R, Hunter DJ, Isaacs C, Lenner P, Lund E, Overvad K, Palli D, Pearce CL, Quiros JR, Riboli E, Stram DO, Thomas G, Thun MJ, Trichopoulos D, van Gils CH, Ziegler RG: Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer; 2009 Jul 29;9:257
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
  • Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones.
  • We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3).
  • METHODS: We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases.
  • The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II), European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC), Nurses' Health Study (NHS), and Women's Health Study (WHS).
  • RESULTS: Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors.
  • CONCLUSION: Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1043-50 [10613335.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1298-303 [17057720.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27 [10718501.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):757-65 [11440961.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):544-52 [11750729.001]
  • [Cites] Cancer. 2002 May 1;94(9):2490-501 [12015775.001]
  • [Cites] Hum Hered. 2002;53(2):79-91 [12037407.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] Hum Hered. 2003;55(1):27-36 [12890923.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D528-32 [14681474.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Dec;81(12):4388-95 [8954047.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):1091-9 [15546906.001]
  • [Cites] Genet Epidemiol. 2005 Apr;28(3):261-72 [15637718.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15 [17018787.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • (PMID = 19640273.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA098216; United States / NCI NIH HHS / CA / U01 CA098710; United States / NCI NIH HHS / CA / U01CA098233; United States / NCI NIH HHS / CA / U01CA098758
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GNRHR protein, human; 0 / Protein Precursors; 0 / Receptors, LHRH; 0 / progonadoliberin I; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Other-IDs] NLM/ PMC2729775
  •  go-up   go-down


61. Cannon PS, Huilgol SC, Selva D, Malhotra R: Basal cell carcinoma. Ophthalmology; 2009 Nov;116(11):2266-7; author reply 2267
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ophthalmology. 2009 Apr;116(4):802-6 [19232734.001]
  • (PMID = 19883865.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


62. Cherpelis BS, Turner L, Ladd S, Glass LF, Fenske NA: Innovative 19-minute rapid cytokeratin immunostaining of nonmelanoma skin cancer in Mohs micrographic surgery. Dermatol Surg; 2009 Jul;35(7):1050-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innovative 19-minute rapid cytokeratin immunostaining of nonmelanoma skin cancer in Mohs micrographic surgery.
  • BACKGROUND: Dense inflammation can obscure nonmelanoma skin cancer (NMSC) on frozen sections, prompting removal of additional layers to ensure negative margins.
  • OBJECTIVE: Our objective was to develop an effective ultrarapid CK frozen section immunostain to be used during MMS in cases of NMSC with dense or perineural inflammation.
  • METHODS: An ultrarapid immunostain with a mixture of AE1/AE3 monoclonal antibodies was performed in 21 MMS cases and compared with permanent sections prepared from the same material.
  • RESULTS: The ultrarapid CK protocol stained all of the cells in each of the 21 examples of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in frozen tissue in a way equivalent to immunostains being applied to permanent sections.
  • CONCLUSION: The 19-minute CK immunohistochemistry protocol in frozen tissue appears to be as effective at labeling tumor cells of SCC and BCC as methods requiring permanent sections.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Frozen Sections / methods. Immunohistochemistry. Keratins. Mohs Surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal. Antigens, Neoplasm / immunology. Humans. Male. Staining and Labeling. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469800.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 68238-35-7 / Keratins
  •  go-up   go-down


63. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, Munzel U: Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol; 2008 Nov-Dec;18(6):677-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
  • Imiquimod 5% cream is an immune response modifier approved for the treatment of superficial basal cell carcinoma (sBCC) once daily, 5 x per week for 6 weeks.
  • This report reveals the final results of a 5-year follow-up study to evaluate the recurrence rate of sBCCs treated with imiquimod.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasm Recurrence, Local. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955210.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


64. Bozkurt M, Kapi E, Kuvat SV, Ozekinci S: Current concepts in the management of Marjolin's ulcers: outcomes from a standardized treatment protocol in 16 cases. J Burn Care Res; 2010 Sep-Oct;31(5):776-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of Marjolin's ulcers: outcomes from a standardized treatment protocol in 16 cases.
  • Marjolin's ulcer is a malignant lesion observed in chronic wounds and in areas where the integrity of the skin is compromised because of any one of several reasons.
  • The aim of this study was to define etiology, topography, and histopathology for Marjolin's ulcer and its surgical management.
  • Sixteen cases were diagnosed and treated as Marjolin's ulcers.
  • The mean age was 57.1 years (range, 32-85 years) and 15 of the patients (93.75%) had history of ulcer of 30 years or more.
  • In 10 cases (62.5%), Marjolin's ulcer occurred after a flame burn and in 6 cases (37.5%) after a scalding burn injury.
  • In six cases (37.5%), there was history of chronic trauma due to contact with the clothing.
  • Primary lesions were at the leg, gluteal region, thigh, scalp, trunk, and hand in four (25%), three (18.7%), two (12.5%), two (12.5%), three (18.7%), and two (12.5%) cases, respectively.
  • Amputation was carried out to treat two cases, and repair of the defects with partial-thickness skin grafting was performed in 14 cases after tumor resection on the skin.
  • Superficial inguinal lymph node dissections were performed in four cases with tumor in the thigh and a positive inguinal lymph node.
  • Squamous cell carcinoma was diagnosed in 14 cases (87.5%) and basal cell carcinoma in two cases (12.5%) postoperatively.
  • The authors conclude that diagnosis and surgical planning based on the recent literature must be carried out even more intensively to improve the prognosis of Marjolin's ulcer.
  • [MeSH-major] Burns / complications. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Skin Neoplasms / etiology. Skin Neoplasms / surgery. Skin Ulcer / etiology. Skin Ulcer / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Skin Transplantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661151.001).
  • [ISSN] 1559-0488
  • [Journal-full-title] Journal of burn care & research : official publication of the American Burn Association
  • [ISO-abbreviation] J Burn Care Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Mehta S, Price GD, Alfè D: Ab initio thermodynamics and phase diagram of solid magnesium: a comparison of the LDA and GGA. J Chem Phys; 2006 Nov 21;125(19):194507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hcp-bcc phase boundary has also been computed and is found to be in agreement with experimental observation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129123.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Bradford C, Wack A, Trembley S, Southard T, Bronson E: Two cases of neoplasia of basal cell origin affecting the axillary region in anseriform species. J Avian Med Surg; 2009 Sep;23(3):214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of neoplasia of basal cell origin affecting the axillary region in anseriform species.
  • Neoplasms of the skin are occasionally seen in domestic birds but are uncommon in nondomestic birds.
  • Skin biopsies were taken, and bilateral feather folliculomas were diagnosed on histopathologic examination.
  • This mass was diagnosed as a basosquamous carcinoma.
  • Basosquamous carcinoma may have a similar gross appearance.
  • This appears to be the first report of feather folliculoma and basosquamous carcinoma in Anseriforme species.
  • Feather folliculomas and other neoplasms, such as basosquamous carcinoma, should be considered as a differential diagnosis in ulcerative or proliferative skin lesions in birds.
  • [MeSH-major] Bird Diseases / pathology. Ducks. Neoplasms, Basal Cell / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999766.001).
  • [ISSN] 1082-6742
  • [Journal-full-title] Journal of avian medicine and surgery
  • [ISO-abbreviation] J. Avian Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Koro C, Barrett S, Qizilbash N: Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf; 2007 May;16(5):485-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
  • PURPOSE: We conducted three nested case-control studies to evaluate the risk of breast, colon, and prostate cancers developing in patients exposed to thiazolidinediones (TZDs) compared with other anti-diabetic agents.
  • METHODS: Cancer cases were matched to five controls by age, gender, calendar year, and time in the database from a cohort of 1 26 971 diabetic patients taking anti-diabetic medication in the US Integrated Healthcare Information Services database.
  • Five hundred thirteen breast cancer cases were matched with 2557 controls, 408 cases of colon cancer were matched with 2027 controls and 643 cases of prostate cancer were matched with 3176 controls.
  • RESULTS: The adjusted odds ratios and 95%CI of cancer from ever exposure to TZDs compared to oral monotherapy, oral dual therapy, oral triple therapy, insulin monotherapy, insulin and oral therapy and all non-TZD anti-diabetic agents were, respectively for breast cancer: 0.91 (0.69-1.20), 0.80 (0.56-1.14), 0.87 (0.32-2.35), 1.27 (0.61-2.67), 0.71 (0.36-1.37), 0.89 (0.68-1.15); for colon cancer: 1.06 (0.80-1.40), 1.12 (0.77-1.63), 1.73 (0.39-7.78), 4.46 (1.05-19.00), 1.06 (0.50-2.26) 1.03 (0.80-1.32) and for prostate cancer: 1.08 (0.85-1.37), 0.89 (0.66-1.21); 0.82 (0.33-2.06); 1.80 (0.79-4.07), 1.10 (0.55-2.18), 1.04 (0.83-1.31).
  • Results for exposure within 90 days of the date of the cancer were similar.
  • CONCLUSIONS: Our findings suggest that the effect of TZDs on the likelihood of development of the cancers studied (colon, prostate and breast) appears to be neutral and do not support a beneficial or deleterious effect of TZD on the cancers studied.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Breast Neoplasms / chemically induced. Breast Neoplasms / epidemiology. Case-Control Studies. Colonic Neoplasms / chemically induced. Colonic Neoplasms / epidemiology. Databases, Factual / statistics & numerical data. Delivery of Health Care / statistics & numerical data. Female. Follow-Up Studies. Humans. Male. Middle Aged. Odds Ratio. Prostatic Neoplasms / chemically induced. Prostatic Neoplasms / epidemiology. Risk Assessment / methods. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 17192841.001).
  • [ISSN] 1053-8569
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Thiazolidinediones
  •  go-up   go-down


68. Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani, Murthy NS: Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India--a cross-sectional study. World J Surg Oncol; 2005 Oct 13;3:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India--a cross-sectional study.
  • BACKGROUND: Breast cancer is the second most common malignancy among women, next to cervix cancer.
  • Understanding its pathogenesis, morphological features and various risk-factors, including family history holds a great promise for the treatment, early detection and prevention of this cancer.
  • PATIENTS AND METHODS: In an attempt to evaluate the clinico-morphological patterns of breast cancer patients, including their family history of breast and/or other cancers, a detailed analysis of 569 breast cancer cases diagnosed during the years 1989-2003 was carried out.
  • Among the various histo-morphological types, Infiltrating duct carcinoma (IDC) was found to be commonest type i.e. in 502 cases (88.2%), followed by infiltrating lobular carcinoma (ILC) in 21 cases (3.7%) and other types forming 9(1%).
  • Out of 369 cases where TNM staging was available, stage IIIB (35.2%) was the commonest.
  • Lymph node positivity was observed in 296 cases (80.2%).
  • Out of 226 cases evaluated for presence of family history, 47 cases (20.7%) revealed positive family history of cancer, among which breast or ovarian cancer were the commonest type (72.0%).
  • Amongst familial cases, Infiltrating duct carcinoma was the commonest form accounting for 68.8% cases while ILC was found to be in a higher proportion (12.5%) as compared to non- familial cases (5.4%).
  • CONCLUSION: Among the various determining factors for development of breast cancer and for its early detection, family history of cancer forms one of the major risk factor.
  • Educating the population about the risk factors would be helpful in early detection of breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1747-54 [1516030.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3351-6 [1104147.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Indian J Cancer. 1975 Sep;12(3):231-42 [1193654.001]
  • [Cites] Hum Mutat. 2002 Dec;20(6):473-4 [12442273.001]
  • [Cites] Indian J Cancer. 1998 Mar;35(1):10-8 [9847465.001]
  • [Cites] Am J Clin Pathol. 1975 Dec;64(6):720-7 [173175.001]
  • [Cites] Surg Gynecol Obstet. 1963 Aug;117:196-200 [14048012.001]
  • [Cites] Acta Oncol. 1991;30(5):569-74 [1892673.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):961-72 [2188501.001]
  • [Cites] Int J Cancer. 1972 Nov;10(3):443-50 [4668492.001]
  • [Cites] Cancer. 1971 Dec;28(6):1500-4 [5127797.001]
  • [Cites] Int J Cancer. 1970 May 15;5(3):426-31 [5452072.001]
  • [Cites] J Surg Oncol. 1981;18(3):269-79 [6273657.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):381-400 [8004612.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):129-32 [8018523.001]
  • [Cites] Epidemiol Rev. 1993;15(1):36-47 [8405211.001]
  • [Cites] Annu Rev Med. 1998;49:425-36 [9509273.001]
  • (PMID = 16236180.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1277852
  •  go-up   go-down


69. Dutta V, Chopra GS, Sahai K, Nema SK: Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer. Med J Armed Forces India; 2008 Jan;64(1):11-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer.
  • BACKGROUND: There is a great deal of disparity in the incidence of breast cancer in rural and urban India on one hand and between India and Western population on the other.
  • METHODS: We analysed steroid receptor status in cases of breast cancer in a small sample of patients in armed forces.
  • Infiltrating duct carcinomas of breast recorded histologically in mastectomy specimens in last two years were accessioned in the present study with reference to patient and tumour characteristics.
  • Negative steroid receptor status did not correlate with presence or absence of metastatic nodes, however it was predominant amongst the high grade infiltrating duct carcinomas in this study.
  • 70% of the node positive cases expressed Her -2/ Neu, reflecting a higher immunoreactivity in this subset of patients.
  • Aneusomy for chromosomes 1, 11 and 17 was common in node positive cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27408071.001).
  • [ISSN] 0377-1237
  • [Journal-full-title] Medical journal, Armed Forces India
  • [ISO-abbreviation] Med J Armed Forces India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4921764
  • [Keywords] NOTNLM ; Breast carcinoma / Her –2/ Neu / Hormone receptors
  •  go-up   go-down


70. Gu D, Zhuang L, Huang H, Cao P, Wang D, Tang J, Chen J: TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls. Breast Cancer Res Treat; 2010 Oct;123(3):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls.
  • Breast cancer is the most prevalent cancer worldwide.
  • Many published articles have evaluated the association between the transforming growth factor beta 1 (TGFB1) T29C polymorphism and breast cancer risk.
  • A total of 12 studies including 10,417 breast cancer cases and 11,455 controls were identified.
  • Overall, no significant associations between the TGFB1 T29C polymorphism and breast cancer risk were found for CC versus TT (OR = 1.00, 95% CI = 0.92-1.09), TC versus TT (OR = 0.98, 95% CI = 0.93-1.05), CC/TC versus TT (OR = 0.99, 95% CI = 0.93-1.05), and CC versus TC/TT (OR = 1.00, 95% CI = 0.93-1.08).
  • In conclusion, the present meta-analysis suggests that the TGFB1 T29C polymorphism is not a low-penetrant risk factor for developing breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Polymorphism, Genetic. Transforming Growth Factor beta1 / genetics
  • [MeSH-minor] Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Linear Models. Odds Ratio. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20157775.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


71. Savage SA, Chanock SJ, Lissowska J, Brinton LA, Richesson D, Peplonska B, Bardin-Mikolajczak A, Zatonski W, Szeszenia-Dabrowska N, Garcia-Closas M: Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer; 2007 Sep 17;97(6):832-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in five genes important in telomere biology and risk for breast cancer.
  • Telomeres, consisting of TTAGGG nucleotide repeats and a protein complex at chromosome ends, are critical for maintaining chromosomal stability.
  • Genomic instability, following telomere crisis, may contribute to breast cancer pathogenesis.
  • Many genes critical in telomere biology have limited nucleotide diversity, thus, single nucleotide polymorphisms (SNPs) in this pathway could contribute to breast cancer risk.
  • In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped.
  • We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).
  • In conclusion, our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.
  • Intriguing associations with variants in TERT among women with a family history of breast cancer warrant follow-up in independent studies.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1659-68 [10669743.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):193-202 [16752076.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Science. 2001 May 11;292(5519):1171-5 [11349150.001]
  • [Cites] Hum Genet. 2001 Jul;109(1):121-4 [11479744.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):564-79 [11850781.001]
  • [Cites] Hum Hered. 2003;55(1):56-65 [12890927.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):323-9 [15071557.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W242-8 [15215388.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):262-8 [15322492.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1663-7 [7502076.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):231-5 [9326950.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):513-7 [9355973.001]
  • [Cites] J Pathol. 1999 Mar;187(4):396-402 [10398097.001]
  • [Cites] Genet Epidemiol. 2004 Dec;27(4):365-74 [15372618.001]
  • [Cites] Nucleic Acids Res. 2005;33(3):893-902 [15701761.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):977-90 [15743672.001]
  • [Cites] Hum Mutat. 2005 Oct;26(4):343-50 [16110488.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2100-10 [16166375.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 3;341(1):128-31 [16412982.001]
  • [Cites] Hum Genet. 2006 May;119(4):376-88 [16485136.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1466-74 [16737810.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):123-9 [16755295.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):248-54 [11089982.001]
  • (PMID = 17848914.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / Nuclear Proteins; 0 / POT1 protein, human; 0 / TATA Box Binding Protein-Like Proteins; 0 / TEP1 protein, human; 0 / TERF1 protein, human; 0 / TERF2 protein, human; 0 / Telomere-Binding Proteins; 0 / Telomeric Repeat Binding Protein 2; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2360388
  •  go-up   go-down


72. Taylor TR, Williams CD, Makambi KH, Mouton C, Harrell JP, Cozier Y, Palmer JR, Rosenberg L, Adams-Campbell LL: Racial discrimination and breast cancer incidence in US Black women: the Black Women's Health Study. Am J Epidemiol; 2007 Jul 1;166(1):46-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial discrimination and breast cancer incidence in US Black women: the Black Women's Health Study.
  • Perceived discrimination may contribute to somatic disease.
  • The association between perceived discrimination and breast cancer incidence was assessed in the Black Women's Health Study.
  • Cox proportional hazards models were used to estimate incidence rate ratios, controlling for breast cancer risk factors.
  • From 1997 to 2003, 593 incident cases of breast cancer were ascertained.
  • In the total sample, there were weak positive associations between cancer incidence and everyday and major discrimination.
  • These findings suggest that perceived experiences of racism are associated with increased incidence of breast cancer among US Black women, particularly younger women.
  • [MeSH-major] African Americans. Breast Neoplasms / epidemiology. Prejudice

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400570.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA058420
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


73. Tjønneland A, Christensen J, Olsen A, Stripp C, Thomsen BL, Overvad K, Peeters PH, van Gils CH, Bueno-de-Mesquita HB, Ocké MC, Thiebaut A, Fournier A, Clavel-Chapelon F, Berrino F, Palli D, Tumino R, Panico S, Vineis P, Agudo A, Ardanaz E, Martinez-Garcia C, Amiano P, Navarro C, Quirós JR, Key TJ, Reeves G, Khaw KT, Bingham S, Trichopoulou A, Trichopoulos D, Naska A, Nagel G, Chang-Claude J, Boeing H, Lahmann PH, Manjer J, Wirfält E, Hallmans G, Johansson I, Lund E, Skeie G, Hjartåker A, Ferrari P, Slimani N, Kaaks R, Riboli E: Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control; 2007 May;18(4):361-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC).
  • OBJECTIVE: Most epidemiologic studies have suggested an increased risk of breast cancer with increasing alcohol intake.
  • Using data from 274,688 women participating in the European Prospective Investigation into Cancer and Nutrition study (EPIC), we investigated the relation between alcohol intake and the risk of breast cancer.
  • RESULTS: During 6.4 years of follow up, 4,285 invasive cases of breast cancer within the age group 35-75 years were identified.
  • When adjusted, no association was seen between lifetime alcohol intake and risk of breast cancer.
  • CONCLUSION: This large European study supports previous findings that recent alcohol intake increases the risk of breast cancer.
  • [MeSH-major] Alcohol Drinking / adverse effects. Breast Neoplasms / epidemiology. Ethanol / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364225.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


74. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U: Multidrug resistance in locally advanced breast cancer. Tumour Biol; 2006;27(6):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance in locally advanced breast cancer.
  • BACKGROUND: Advanced breast cancer cases can still be encountered resulting in poor prognosis.
  • In this study, the role of MDR is evaluated in locally advanced breast cancer patients.
  • RESULTS: Breast tissues from 25 patients both before and after chemotherapy were examined.
  • CONCLUSION: In locally advanced breast cancer, ABCB1 gene expression during chemotherapy contributes to clinical unresponsiveness.
  • [MeSH-major] Breast Neoplasms / drug therapy. Drug Resistance, Multiple. Multidrug Resistance-Associated Proteins / genetics. Organic Anion Transporters / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 17033200.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / DNA Primers; 0 / DNA, Complementary; 0 / Multidrug Resistance-Associated Proteins; 0 / Organic Anion Transporters; 0 / P-Glycoprotein; 0 / P-Glycoproteins; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


75. Hafner C: [Targeted therapy of basal cell carcinoma through inhibition of the hedgehog signaling pathway]. Hautarzt; 2010 Apr;61(4):356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Targeted therapy of basal cell carcinoma through inhibition of the hedgehog signaling pathway].
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Drug Delivery Systems / methods. Hedgehog Proteins / antagonists & inhibitors. Signal Transduction / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12 ):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12 ):1164-72 [19726763.001]
  • [Cites] Science. 2009 Oct 23;326(5952):572-4 [19726788.001]
  • (PMID = 20309511.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins
  •  go-up   go-down


76. Ethunandan M, Downie I, Flood T: Implant-retained nasal prosthesis for reconstruction of large rhinectomy defects: the Salisbury experience. Int J Oral Maxillofac Surg; 2010 Apr;39(4):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Post-rhinectomy defect modification enables adequate access for safe placement of long implants with good primary stability and helps the maintenance of good hygiene (further enhanced by the use of skin grafts).
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carcinoma, Basal Cell / rehabilitation. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / rehabilitation. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Hyperbaric Oxygenation. Magnetics / instrumentation. Male. Middle Aged. Nasal Septum / surgery. Prosthesis Design. Prosthesis Failure. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Skin Care. Skin Transplantation. Smoking. Treatment Outcome. Turbinates / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20149598.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


77. Xing X, Xue C, Li J: [Reconstruction of nasal defect after tumor excision]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Jul;21(7):714-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From April 1996 to April 2006, based on the aesthetic subunit principle and according to the size, shape, location of nasal defect and the conditions of surrounding skin, homologous local flap was selected to cover the nasal defect in 428 cases which nasal tumors were removed.
  • Among 428 cases, there were 273 men and 155 women, with a median age of 52 years (12-78 years); including 146 cases of basal cell carcinoma, 83 cases of squamous cell carcinoma, 54 cases of epidermal cyst, and 145 cases of pigmented naevus.
  • The clinical stage of malignant tumor was 0-I stage, the course of disease was 1 week to 3 months.
  • The locations were nasal tip in 51 cases, nasal ala in 102 cases, dorsum of nose in 138 cases, and nasal side in 137 cases, across 2 nasal subunits in 83 cases.
  • The origin of flaps was frontonasal flap in 58 cases, bilobed flap in 67 cases, reforming rhomboid flap in 152 cases, nasolabial flap in 118 cases, forehead falp in 33 cases.
  • RESULTS: Among 428 cases, 423 cases acquired complete recovery; 3 cases which had epiderm necrosis over the far end of the flap achieved healing by the first intention and 2 cases which had suffered low-grade infection of incision achieved healing by the second intention after regional change dressings.
  • CONCLUSION: Based on the nasal aesthetic subunit principle, the local flap can reconstruct the nasal above medial defect, and a good color, contour and texture match with the surrounding skin can be obtained, the cosmetic results are satisfactory.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Skin Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Wound Healing. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694661.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Kazemi M, Salehi Z, Chakosari RJ: TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res; 2009;18(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 codon 72 polymorphism and breast cancer in northern Iran.
  • Its diverse functions include DNA binding, cell cycle control, DNA repair, differentiation, genomic plasticity, and apoptosis.
  • A common polymorphism of the p53 gene at codon 72 has been associated with human cancer susceptibility and prognosis.
  • In this study, we investigated p53 codon 72 polymorphism in 42 breast cancer cases and 60 healthy individual in northern Iran.
  • The distribution of genotypes in breast cancer cases and controls were different (p = 0.001).
  • Pro allele was significantly associated with the presence of breast cancer (odds ratio = 1.5 and 95% confidence interval = 0.85-2.63).
  • Pro/Pro genotype was overrepresented in breast cancer.
  • Based on these data, it is suggested that Pro allele may modify the risk of breast cancer in northern Iranian women.
  • [MeSH-major] Breast Neoplasms / genetics. Codon / genetics. Genes, p53 / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911701.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


79. Bikle DD: Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J Invest Dermatol; 2008 Oct;128(10):2357-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism.
  • More than 1 million skin cancers occur annually in the United States--of which 80% are basal-cell carcinoma (BCC), 16% are squamous-cell carcinoma (SCC), and 4% are melanomas--making skin cancer by far the most common cancer (Greenlee et al., 2001).
  • Thus, UVB, with a spectrum between 280 and 320 nm, is the major cause of these cancers (Freeman et al., 1989), but this is the same spectrum required for vitamin D production in the skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Invest Dermatol. 2008 Oct;128(10):2508-17 [18509362.001]
  • (PMID = 18787544.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR038386; United States / NIAMS NIH HHS / AR / R01 AR050023; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NIAMS NIH HHS / AR / R01 AR0550023
  • [Publication-type] Comment; Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Tumor Suppressor Proteins; 1406-16-2 / Vitamin D
  •  go-up   go-down


80. Bulliard JL, Panizzon RG, Levi F: [Epidemiology of epithelial skin cancers]. Rev Med Suisse; 2009 Apr 22;5(200):882, 884-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of epithelial skin cancers].
  • [Transliterated title] Epidémiologie des cancers épithéliaux de la peau.
  • With no less than 15,000 estimated new cases diagnosed per year, non melanomatous carcinomas are the commonest cutaneous cancers in the Swiss population.
  • About 1 in 3 new cancer case is a basal (BCC) or a squamous cell carcinoma (SCC).
  • Incidence rates are steadily increasing, faster for BCC than SCC.
  • Systematic population-based registration of non melanomatous skin cancers faces many challenges that few cancer registries can meet.
  • Primary and secondary nationwide prevention campaigns have been carried out for nearly 20 years with a focus on the deadliest cutaneous cancer: melanoma.
  • However, detection of non melanomatous skin cancers benefits from these campaigns since prevention messages and means of early detection are similar for melanomas and other skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438088.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


81. Yun SK, Kim SM, Park J, Lee JS, Yi JH, Kim HU, Ihm CW: Large superficial basal cell carcinoma arising from moxa cautery. Eur J Dermatol; 2009 Jul-Aug;19(4):387-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large superficial basal cell carcinoma arising from moxa cautery.
  • [MeSH-major] Burns / complications. Carcinoma, Basal Cell / etiology. Moxibustion / adverse effects. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451052.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


82. Koopman MM, Fuselier DM, Hird S, Carstens BC: The carnivorous pale pitcher plant harbors diverse, distinct, and time-dependent bacterial communities. Appl Environ Microbiol; 2010 Mar;76(6):1851-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The carnivorous pale pitcher plant harbors diverse, distinct, and time-dependent bacterial communities.
  • The ability of American carnivorous pitcher plants (Sarracenia) to digest insect prey is facilitated by microbial associations.
  • Knowledge of the details surrounding this interaction has been limited by our capability to characterize bacterial diversity in this system.
  • To describe microbial diversity within and between pitchers of one species, Sarracenia alata, and to explore how these communities change over time as pitchers accumulate and digest insect prey, we collected and analyzed environmental sequence tag (454 pyrosequencing) and genomic fingerprint (automated ribosomal intergenic spacer analysis and terminal restriction fragment length polymorphism) data.
  • Microbial richness associated with pitcher plant fluid is high; more than 1,000 unique phylogroups were identified across at least seven phyla and 50 families.
  • We documented an increase in bacterial diversity and abundance with time and observed repeated changes in bacterial community composition.
  • Pitchers from different plants harbored significantly more similar bacterial communities at a given time point than communities coming from the same genetic host over time.
  • The microbial communities in pitcher plant fluid also differ significantly from those present in the surrounding soil.
  • These findings indicate that the bacteria associated with pitcher plant leaves are far from random assemblages and represent an important step toward understanding this unique plant-microbe interaction.
  • [MeSH-major] Bacteria / classification. Bacteria / isolation & purification. Biodiversity. Sarraceniaceae / microbiology
  • [MeSH-minor] Cluster Analysis. DNA Fingerprinting. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal Spacer / chemistry. DNA, Ribosomal Spacer / genetics. Metagenome. Phylogeny. Polymorphism, Restriction Fragment Length. Sequence Analysis, DNA. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microb Ecol. 2002 Apr;43(3):307-14 [12037609.001]
  • [Cites] Appl Environ Microbiol. 2001 Jan;67(1):190-7 [11133445.001]
  • [Cites] Appl Environ Microbiol. 2003 Apr;69(4):1875-83 [12676659.001]
  • [Cites] Am Nat. 2003 Aug;162(2):165-71 [12858261.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6768-76 [14602639.001]
  • [Cites] Curr Opin Microbiol. 2004 Jun;7(3):221-6 [15196488.001]
  • [Cites] Annu Rev Phytopathol. 2004;42:243-70 [15283667.001]
  • [Cites] Appl Environ Microbiol. 2004 Oct;70(10):6147-56 [15466561.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4516-22 [9361437.001]
  • [Cites] Appl Environ Microbiol. 2005 Jan;71(1):227-39 [15640192.001]
  • [Cites] Environ Microbiol. 2005 Jan;7(1):78-87 [15643938.001]
  • [Cites] Microb Ecol. 2004 Nov;48(4):550-60 [15696388.001]
  • [Cites] Nature. 2005 Sep 15;437(7057):376-80 [16056220.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1917 [16809531.001]
  • [Cites] Microb Ecol. 2006 Oct;52(3):470-9 [16909344.001]
  • [Cites] Appl Environ Microbiol. 2007 Jan;73(2):659-62 [17122397.001]
  • [Cites] Appl Environ Microbiol. 2007 Apr;73(7):2399-401; author reply 2399-401 [17403942.001]
  • [Cites] Microb Ecol. 2007 Aug;54(2):324-31 [17380356.001]
  • [Cites] Appl Environ Microbiol. 2007 Aug;73(16):5261-7 [17586664.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e120 [17881377.001]
  • [Cites] ISME J. 2007 May;1(1):38-47 [18043612.001]
  • [Cites] Nat Methods. 2008 Mar;5(3):235-7 [18264105.001]
  • [Cites] Environ Microbiol. 2008 Jun;10(6):1411-8 [18205822.001]
  • [Cites] Ecology. 2008 Apr;89(4):898-904 [18481512.001]
  • [Cites] Nature. 2008 May 29;453(7195):687-90 [18509446.001]
  • [Cites] ISME J. 2008 Jul;2(7):689-95 [18463690.001]
  • [Cites] Environ Microbiol. 2008 Sep;10(9):2257-66 [18479443.001]
  • [Cites] Nature. 2008 Sep 25;455(7212):481-3 [18818648.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17994-9 [19004758.001]
  • [Cites] Microb Ecol. 2009 Jul;58(1):189-98 [19221834.001]
  • [Cites] BMC Bioinformatics. 2009;10:171 [19500385.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2284-91 [11319113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10494-9 [12097644.001]
  • (PMID = 20097807.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal Spacer
  • [Other-IDs] NLM/ PMC2838028
  •  go-up   go-down


83. Tang X, Gao G, Zhu L, Chao J, Qin B: DNA extraction procedure affects organic-aggregate-attached bacterial community profiles from a shallow eutrophic lake. Can J Microbiol; 2009 Jun;55(6):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA extraction procedure affects organic-aggregate-attached bacterial community profiles from a shallow eutrophic lake.
  • Organic aggregates (OA) in aquatic ecosystems harbour diverse microbial communities.
  • The colonization and growth of OA-attached bacteria are important processes in the degradation and transformation of the particles.
  • The development of efficient and comparative DNA extraction methods is one of the most critical steps in the study of the composition and diversity of OA-attached bacterial communities.
  • To evaluate whether different DNA extraction procedures affect the measurement of bacterial community composition, we compared four in situ lysis procedures using OA from three locations in a shallow eutrophic lake (Lake Taihu, China).
  • The extracted DNA was analyzed using denaturing gradient gel electrophoresis profiles.
  • We found that the choice of DNA extraction protocol had a significant influence on the fingerprints of the OA-attached bacterial community.
  • This was shown not only in the number of bands but also in their relative representation of certain DNA bands.
  • Using the bead-beating DNA extraction method in the presence of hexadecyltrimethylammonium bromide, we found that crude microbial DNA could be extracted efficiently from different OA types.
  • This protocol is reproducible and gives very pure DNA of relatively high molecular mass.
  • More importantly, the protocol provided more representative and informative data on the diversity of OA-attached bacterial communities.
  • [MeSH-major] Bacteria / isolation & purification. DNA, Bacterial / isolation & purification. Fresh Water / microbiology. Genetic Techniques
  • [MeSH-minor] Bacterial Adhesion. Geologic Sediments / microbiology. Molecular Sequence Data. Phylogeny

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767849.001).
  • [ISSN] 1480-3275
  • [Journal-full-title] Canadian journal of microbiology
  • [ISO-abbreviation] Can. J. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / DNA, Bacterial
  •  go-up   go-down


84. Yan Q, Yu Y, Feng W, Yu Z, Chen H: Plankton community composition in the Three Gorges Reservoir Region revealed by PCR-dGGE and its relationships with environmental factors. J Environ Sci (China); 2008;20(6):732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first two CCA ordination axes suggested that the bacterial community composition was primarily correlated with the variables of NO(3-)-N, dissolved oxygen (DO), and SiO3(2-)-Si, whereas, the eukaryotic community was mainly correlated with the concentrations of DO, PO4(3-)-P, and SiO3(2-)-Si.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763569.001).
  • [ISSN] 1001-0742
  • [Journal-full-title] Journal of environmental sciences (China)
  • [ISO-abbreviation] J Environ Sci (China)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Ribosomal
  •  go-up   go-down


85. Rosen N, Muhn CY, Bernstein SC: A common tumor, an uncommon location: basal cell carcinoma of the nipple and areola in a 49-year-old woman. Dermatol Surg; 2005 Apr;31(4):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A common tumor, an uncommon location: basal cell carcinoma of the nipple and areola in a 49-year-old woman.
  • BACKGROUND: Basal cell carcinoma (BCC) occurring on sun-protected regions is an uncommon phenomenon.
  • BCC of the nipple is an exceedingly rare event.
  • METHOD: We review the literature on BCC of the female nipple and herein describe the eighth reported case in the English literature.
  • CONCLUSION: BCC of the nipple are extremely rare tumors with unclear etiology.
  • With continued reporting of the diagnosis, treatment, and follow-up of these patients, we may gain an understanding of the pathogenesis, as well as the best method of control for these unusual tumors.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Basal Cell / surgery. Mohs Surgery. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871330.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


86. Friedman GD: Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep? J Sleep Res; 2008 Sep;17(3):243-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep?
  • [MeSH-major] Acetamides / adverse effects. Azabicyclo Compounds / adverse effects. Carcinoma, Basal Cell / chemically induced. Indenes / adverse effects. Piperazines / adverse effects. Pyrimidines / adverse effects. Skin Neoplasms / chemically induced. Sleep Initiation and Maintenance Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Insomnia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESZOPICLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Sleep Res. 2008 Sep;17(3):245-50 [18844818.001]
  • (PMID = 18844817.001).
  • [ISSN] 1365-2869
  • [Journal-full-title] Journal of sleep research
  • [ISO-abbreviation] J Sleep Res
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acetamides; 0 / Azabicyclo Compounds; 0 / Indenes; 0 / Piperazines; 0 / Pyrimidines; 151319-34-5 / zaleplon; 901AS54I69 / ramelteon; UZX80K71OE / Eszopiclone
  •  go-up   go-down


87. Bamford S, Ryley H, Jackson SK: Highly purified lipopolysaccharides from Burkholderia cepacia complex clinical isolates induce inflammatory cytokine responses via TLR4-mediated MAPK signalling pathways and activation of NFkappaB. Cell Microbiol; 2007 Feb;9(2):532-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly purified lipopolysaccharides from Burkholderia cepacia complex clinical isolates induce inflammatory cytokine responses via TLR4-mediated MAPK signalling pathways and activation of NFkappaB.
  • In cystic fibrosis (CF), bacteria of the Burkholderia cepacia complex (Bcc) can induce a fulminant inflammation with pneumonitis and sepsis.
  • Lipopolysaccharide (LPS) may be an important virulence factor associated with this decline but little is known about the molecular pathogenesis of Bcc LPS.
  • In this study we have investigated the inflammatory response to highly purified LPS from different Bcc clinical isolates and the cellular signalling pathways employed.
  • LPS from all clinical Bcc isolates induced significant pro-inflammatory cytokines and utilized TLR4 and CD14 to mediate activation of mitogen-activated protein kinase pathways, IkappaB-alpha degradation and NFkappaB activation.
  • This study suggests that LPS alone from clinical isolates of Bcc is an important virulence factor in CF and utilizes TLR4-mediated signalling pathways to induce a significant inflammatory response.
  • [MeSH-major] Burkholderia cepacia complex / chemistry. Cytokines / metabolism. Lipopolysaccharides / pharmacology. MAP Kinase Kinase 1 / metabolism. NF-kappa B / metabolism. Signal Transduction / drug effects

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002785.001).
  • [ISSN] 1462-5814
  • [Journal-full-title] Cellular microbiology
  • [ISO-abbreviation] Cell. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4; EC 2.7.12.2 / MAP Kinase Kinase 1
  •  go-up   go-down


88. Medvedeva NI, Van Aken D, Medvedeva JE: Magnetism in bcc and fcc Fe with carbon and manganese. J Phys Condens Matter; 2010 Aug 11;22(31):316002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetism in bcc and fcc Fe with carbon and manganese.
  • Density functional theory calculations were performed to study the structure and magnetic properties of bcc (α) and fcc (γ) Fe with 3 at.
  • We find that all bcc-based Fe, Fe-C and Fe-Mn-C phases exhibit a ferromagnetic (FM) ground state, while the antiferromagnetic double-layer (AFMD) state is lowest in energy within the collinear spin approach in fcc Fe, Fe-C and Fe-Mn-C phases.
  • The states with opposite manganese magnetic moments are quasi-degenerate in bcc Fe-Mn alloy, whereas octa-site carbon stabilizes ferromagnetic coupling of the nearest manganese atom with the Fe host.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21399372.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


89. Lawrence CM, Coaker T, Watson S, Langtry J: Cost of formalin-fixed vs. frozen section Mohs surgery tissue preparation. Br J Dermatol; 2009 Aug;161(2):488-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Frozen Sections / economics. Mohs Surgery / economics. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519835.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 1HG84L3525 / Formaldehyde
  •  go-up   go-down


90. Eggers G, Flechtenmacher C, Kurzen H, Hassfeld S: Infiltrating basal cell carcinoma of the neck 34 years after irradiation of an haemangioma in early childhood. A case-report. J Craniomaxillofac Surg; 2005 Jun;33(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating basal cell carcinoma of the neck 34 years after irradiation of an haemangioma in early childhood. A case-report.
  • A case of a 34-year-old Caucasian male is presented with a basal cell carcinoma deeply infiltrating the structures of the neck, including skeletal muscles and reaching the parotid gland.
  • Thirty years ago the patient had undergone radiotherapy for an infantile haemangioma of the skin of the neck.
  • The effects of this treatment when given in childhood in the aetiology of a basal cell carcinoma are discussed.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Head and Neck Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Hemangioma / radiotherapy. Humans. Male. Skin Neoplasms / radiotherapy. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878521.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


91. Dos Santos JN, Oliveira GQ, Gurgel CA, de Souza RO, Sales CB, de Aguiar Pires Valença Neto A, Ramos EA: Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors. J Mol Histol; 2009 Aug;40(4):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratocystic odontogenic tumor (KOT) is a benign cystic tumor that affects the jaw bones and may be associated with the nevoid basal cell carcinoma syndrome (NBCCS).
  • Twenty-five cases diagnosed as KOT, including primary and recurrent tumors and those associated with NBCCS, were submitted to immunohistochemical study for analysis of cytokeratins (CKs) 7, 8, 10, 13, 14, 18 and 19.
  • CK14 was expressed in all epithelial layers and in those areas where inflammation and subepithelial splits were present; this protein was preserved within the basal cells.
  • CK 18 was expressed mainly in the basal layer, whereas CK19 was expressed mainly on the intermediate and superficial layers.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Jaw Neoplasms / pathology. Keratins / biosynthesis. Neoplasm Recurrence, Local / pathology. Odontogenic Cysts / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 May;99(5):527-8 [15829870.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Aug;58(8):862-5; discussion 866 [10935585.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Mar;91(3):328-33 [11250631.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Apr;107(4):e43-6 [19201226.001]
  • [Cites] J Oral Pathol Med. 1989 Feb;18(2):63-7 [2473204.001]
  • [Cites] Oral Oncol. 2004 May;40(5):545-51 [15006629.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):x-xi [15482464.001]
  • [Cites] J Oral Sci. 2008 Mar;50(1):15-8 [18403878.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):231-9 [10468793.001]
  • [Cites] J Oral Pathol. 1987 Aug;16(7):338-46 [2444682.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Jul;45(5):567-78 [10512189.001]
  • [Cites] J Int Med Res. 2002 Mar-Apr;30(2):131-6 [12025520.001]
  • [Cites] J Cutan Pathol. 2003 Apr;30(4):237-41 [12680953.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):732-7 [12464899.001]
  • [Cites] J Oral Sci. 2008 Jun;50(2):205-12 [18587212.001]
  • [Cites] J Oral Pathol Med. 2005 Oct;34(9):558-64 [16138895.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Periodontal Res. 1993 Jan;28(1):49-59 [7678864.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] Laryngoscope. 2000 Aug;110(8):1328-32 [10942135.001]
  • [Cites] Exp Mol Pathol. 2006 Aug;81(1):72-6 [16445908.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):303-8 [16932021.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8219-27 [17213200.001]
  • [Cites] J Oral Sci. 2006 Jun;48(2):59-62 [16858133.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2007 Mar 01;12(2):E85-91 [17322811.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):361-6 [17388930.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Apr;25(2):124-9 [8727585.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):75-80 [16430736.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Oct;64(4):439-44 [2443892.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Sep;58(9):935-40; discussion 940-1 [10981972.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6 [8634660.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):529-40 [15234234.001]
  • [Cites] J Pathol. 1988 Dec;156(4):283-90 [2465398.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] J Mol Histol. 2008 Jun;39(3):311-6 [18256893.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):639-43 [17671713.001]
  • [Cites] Oral Dis. 2003 Jan;9(1):1-6 [12617250.001]
  • (PMID = 19915949.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


92. Suzuki T, Uno K, Kubo A: [Usefulness of 18F-FDG PET in the diagnosis for breast cancer patients]. Nihon Rinsho; 2006 Mar;64(3):504-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of 18F-FDG PET in the diagnosis for breast cancer patients].
  • Whole-body 18F-FDG PET is useful for qualitative diagnosis of breast mass and for preoperative staging, evaluation of therapeutic effect, prediction of prognosis, and detection of recurrence or metastasis in case of breast cancer.
  • In addition, 18F-FDG PET is being actively used for cancer screening in Japan.
  • 18F-FDG PET has almost equal or higher. capacity in detecting recurrence or metastasis of breast cancer as compared with conventional morphological study such as CT or MRI.
  • However it should be noticed of the existence of false-negative and false-positive findings in some cases.
  • In this paper we refer to the advantages and disadvantages of 18F-FDG PET in managing patients with breast cancer.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging / methods. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529042.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 14
  •  go-up   go-down


93. Freak J: Identification of skin cancers 2: malignant lesions. Br J Community Nurs; 2005 Feb;10(2):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of skin cancers 2: malignant lesions.
  • With the incidence of skin cancers doubling in the last 20 years, it is becoming more and more important for health professionals to be able to identify these dangerous malignancies.
  • In this, the second of two articles, the author discusses the three main types of malignant cutaneous lesion, and provides information on prevention that can be passed on to patients of all ages.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788942.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


94. Dantzig PI: Breast cancer, dermatofibromas and arsenic. Indian J Dermatol; 2009;54(1):23-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer, dermatofibromas and arsenic.
  • BACKGROUND: Dermatofibromas are common benign tumors in women, and breast cancer is the most common malignancy in women.
  • MATERIALS AND METHODS: Five patients with dermatofibromas and 10 control patients (two groups) had their skin biopsies measured for arsenic by inductively coupled mass spectrometry.
  • Fifty randomly selected patients with breast cancer and 50 control patients were examined for the presence of dermatofibromas.
  • RESULTS: The dermatofibromas were found to have an arsenic concentration of 0.171 micrograms/gram, compared with 0.06 and 0.07 micrograms/gram of the two control groups.
  • Forty-three out of 50 patients with breast cancer had dermatofibromas and 32/50 patients with breast cancer had multiple dermatofibromas, compared to 10/50 control patients with dermatofibromas and only 1/50 with multiple dermatofibromas.
  • Dermatofibromas represent an important sign for women at risk for breast cancer, and arsenic may represent the cause of the majority of cases of breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2006 May 1;42(9):1325-32 [16586393.001]
  • [Cites] J Cutan Pathol. 2000 Jan;27(1):54-6 [10660133.001]
  • [Cites] Toxicol Sci. 1999 May;49(1):5-14 [10367337.001]
  • [Cites] JAMA. 1999 Mar 10;281(10):914-20 [10078488.001]
  • [Cites] Clin Lab Med. 1998 Dec;18(4):615-29 [9891602.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):338-47 [9440762.001]
  • [Cites] Environ Health Perspect. 1997 Jun;105 Suppl 4:891-6 [9255576.001]
  • [Cites] Mutagenesis. 1997 Sep;12(5):353-8 [9379914.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):819-35 [8178795.001]
  • [Cites] J Am Acad Dermatol. 1981 Jul;5(1):1-18 [6268671.001]
  • [Cites] Br J Dermatol. 1966 Jul;78(7):398-402 [5943463.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):735-42 [14966099.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1109-11 [14639393.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):223-76 [12725422.001]
  • [Cites] JAMA. 2002 Feb 13;287(6):734-41 [11851540.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • (PMID = 20049264.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2800865
  • [Keywords] NOTNLM ; Arsenic / breast cancer / dermatofibromas
  •  go-up   go-down


95. Azim HA, Azim HA Jr: Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective. J Egypt Natl Canc Inst; 2007 Dec;19(4):225-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.
  • BACKGROUND: Her-2/nue positive breast cancer is an aggressive disease with a higher potential of invasion and metastasis.
  • It constitutes around 20% of all the breast cancer cases and even a higher incidence has been reported in Egypt.
  • Agents targeting Her-2 have been shown to be associated with improvement in response rate, disease free and overall survival.
  • DIAGNOSIS: Different biomarkers have recently emerged to predict the benefit of trastuzumab and/or lapatinib.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Quinazolines / therapeutic use. Receptor, ErbB-2 / metabolism


96. Alarcon F, Bourgain C, Gauthier-Villars M, Planté-Bordeneuve V, Stoppa-Lyonnet D, Bonaïti-Pellié C: PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history. Genet Epidemiol; 2009 Jul;33(5):379-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
  • Providing valid risk estimates of a genetic disease with variable age of onset is a major challenge for prevention strategies.
  • This article focuses on ascertainment through at least one affected and presents an estimation method based on maximum likelihood, called the Proband's phenotype exclusion likelihood or PEL for estimating age-dependent penetrance using disease status and genotypic information of family members in pedigrees unselected for family history.
  • For that purpose, family samples were simulated under various disease risk models and under various ascertainment patterns.
  • As an illustration, we estimated the disease risk for transthyretin amyloid neuropathy from a French sample and a Portuguese sample and for BRCA1/2 associated breast cancer from a sample ascertained on early-onset breast cancer cases.
  • [MeSH-minor] Age Factors. Amyloid Neuropathies / genetics. Bias (Epidemiology). Breast Neoplasms / genetics. France. Genes, BRCA1. Genes, BRCA2. Humans. Likelihood Functions. Models, Genetic. Models, Statistical. Pedigree. Phenotype. Portugal. Prealbumin / genetics. Risk


97. Schulz T, Proske S, Hartschuh W, Kurzen H, Paul E, Wünsch PH: High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread. Am J Dermatopathol; 2005 Feb;27(1):9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread.
  • It has been debated whether malignant transformation of trichoblastoma occurs.
  • The concept was recently forwarded that basal cell carcinoma is as a malignant neoplasm of follicular germinative cells and should be named trichoblastic carcinoma to show its relationship to trichoblastoma.
  • Almost all basal cell carcinomas are low-grade malignant neoplasms and develop metastases only very rarely, and if so, only after very long duration and untreated growth.
  • Only rare basal cell carcinomas arise in trichoblastomas.
  • Up to now there have only been two reports of high-grade trichoblastic carcinoma arising in trichoblastoma, showing systemic metastatic spread and death.
  • We add two further cases of trichoblastic carcinoma with anaplastic nuclei, arising in trichoblastoma.
  • The other one was a trichoblastic carcinoma at the base of a trichoepithelioma on the right thigh of an 87-year-old woman with Brooke-Spiegler syndrome.
  • Our cases emphasize that high-grade trichoblastic carcinoma develops via malignant transformation of trichoblastoma, and is very rare.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Skin Appendage / secondary. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Female. Humans. Immunoenzyme Techniques. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677970.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Uhlenhake EE, Sangueza OP, Lee AD, Jorizzo JL: Spreading pigmented actinic keratosis: a review. J Am Acad Dermatol; 2010 Sep;63(3):499-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It can mimic different pigmented lesions, which may be benign (eg, solar lentigo) or malignant (eg, lentigo maligna).
  • RESULTS: SPAK is a rarely reported lesion that can be difficult to distinguish from other benign and malignant pigmented lesions, including seborrheic keratosis, melanoma in situ (lentigo maligna type), and lentigo maligna melanoma.
  • Pathologically, the lesion resembles classic AK with increased basal melanization.
  • CONCLUSIONS: SPAK can be associated with adjacent melanoma in situ; therefore, its diagnosis merits increased suspicion for coexisting melanoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment


99. Pittayakhajonwut P, Dramae A, Madla S, Lartpornmatulee N, Boonyuen N, Tanticharoen M: Depsidones from the endophytic fungus BCC 8616. J Nat Prod; 2006 Sep;69(9):1361-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depsidones from the endophytic fungus BCC 8616.
  • Three new depsidones (1-3) have been isolated from the endophytic fungus BCC 8616 and their structures analyzed on the basis of spectroscopic data interpretation.
  • Compound 1 exhibited weak cytotoxic activity against breast and epidermoid carcinoma cell lines.

  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989536.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsides; 0 / Lactones; 3580-77-6 / depsidone
  •  go-up   go-down


100. Kurokawa I, Senba Y, Nishimura K, Habe K, Hakamada A, Isoda K, Yamanaka K, Mizutani H, Tsubura A: Cytokeratin expression in trichilemmal carcinoma suggests differentiation towards follicular infundibulum. In Vivo; 2006 Sep-Oct;20(5):583-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin expression in trichilemmal carcinoma suggests differentiation towards follicular infundibulum.
  • An immunohistochemical study of cytokeratins (CK) in a case of trichilemmal carcinoma (TLC).
  • Trichilemmal carcinoma (TLC) is a rare cutaneous tumor, and is considered as a malignant counterpart of trichilemmoma.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091763.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down